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Causal Inference Using Variation In Treatment Over Time
Abstract
This thesis and related research is motivated by my interest in understanding the use
of time-varying treatments in causal inference from complex longitudinal data, which
play a prominent role in public health, economics, and epidemiology, as well as in
biological and medical sciences. Longitudinal data allow the direct study of temporal
changes within individuals and across populations, therefore give us the edge to utilize
time this important factor to explore causal relationships than static data. There are
also a variety challenges that arise in analyzing longitudinal data. By the very nature
of repeated measurements, longitudinal data are multivariate in various dimensions
and have completed random-error structures, which make many conventional causal
assumptions and related statistical methods are not directly applicable. Therefore,
new methodologies, most likely data-driven, are always encouraged and sometimes
necessary in longitudinal causal inference, as will be seen throughout this thesis
As a result of the various topics explored, this thesis is split into four parts corresponding
to three dierent patterns of variation in treatment. The rst pattern
is the one-directional change of a binary treatment assignment, meaning that each
study participant is only allowed to experience the change from untreated to treated
at the staggered time. Such pattern is observed in a novel cluster-randomized design
called the stepped-wedge. The second pattern is the arbitrary switching of a binary
treatment caused by changes in person-specic characteristics and general time
trend. The patterns is the most common thing one would observe in longitudinal
data and we develop a method utilizing trends in treatment to account for unmeasured
confounding. The third pattern is that the underlying treatment, outcome,
covariates are time-continuous, yet are only observed at discrete time points. Instead
of modeling cross-sectional and pooled longitudinal data, we take a mechanistic view
by modeling reactions among variables using stochastic dierential equations and
investigate whether it is possible to draw sensible causal conclusions from discrete
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measurements.
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ABSTRACT
CAUSAL INFERENCE USING VARIATION IN
TREATMENT OVER TIME
Xinyao Ji
Dylan S. Small
This thesis and related research is motivated by my interest in understanding the use
of time-varying treatments in causal inference from complex longitudinal data, which
play a prominent role in public health, economics, and epidemiology, as well as in
biological and medical sciences. Longitudinal data allow the direct study of temporal
changes within individuals and across populations, therefore give us the edge to utilize
time this important factor to explore causal relationships than static data. There are
also a variety challenges that arise in analyzing longitudinal data. By the very nature
of repeated measurements, longitudinal data are multivariate in various dimensions
and have completed random-error structures, which make many conventional causal
assumptions and related statistical methods are not directly applicable. Therefore,
new methodologies, most likely data-driven, are always encouraged and sometimes
necessary in longitudinal causal inference, as will be seen throughout this thesis
As a result of the various topics explored, this thesis is split into four parts cor-
responding to three different patterns of variation in treatment. The first pattern
is the one-directional change of a binary treatment assignment, meaning that each
study participant is only allowed to experience the change from untreated to treated
at the staggered time. Such pattern is observed in a novel cluster-randomized design
called the stepped-wedge. The second pattern is the arbitrary switching of a bi-
nary treatment caused by changes in person-specific characteristics and general time
trend. The patterns is the most common thing one would observe in longitudinal
data and we develop a method utilizing trends in treatment to account for unmea-
sured confounding. The third pattern is that the underlying treatment, outcome,
covariates are time-continuous, yet are only observed at discrete time points. Instead
of modeling cross-sectional and pooled longitudinal data, we take a mechanistic view
by modeling reactions among variables using stochastic differential equations and
investigate whether it is possible to draw sensible causal conclusions from discrete
measurements.
iv
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Introduction
This thesis and related research is motivated by my interest in understanding the
use of time-varying treatments in causal inference from complex longitudinal data,
which play a prominent role in public health, economics, and epidemiology, as well
as in biological and medical sciences. By measuring study participants over time,
longitudinal data allow the direct study of temporal changes within individuals and
across populations, therefore facilitate estimating the causal effect of certain treat-
ment on the outcome. There are also a variety challenges that arise in analyzing
longitudinal data. By their very nature, the repeated measures are multivariate and
have a complex random-error structure that must be appropriated accounted for in
the analysis. Hence, conventional causal assumptions and related statistical methods
are not directly applicable to the topics that I explored in the thesis. They are either
extended or modified and coupled with new methodologies depending on each data-
driven problem.
As a result of the various topics explored, this thesis is split into four parts cor-
responding to three different patterns of variation in treatment. The first pattern
is the one-directional change of a binary treatment assignment, meaning that each
study participant is only allowed to experience the change from untreated to treated
1
at staggered time. Such pattern is observed in a novel cluster-randomized design
called the stepped-wedge. The second pattern is the arbitrary switching of a binary
treatment caused by changes in person-specific characteristics and general time trend.
The third pattern is that the underlying treatment, outcome, and other covariates
are time-continuous, and that they are only observed at discrete time points.
The majority of the work in this document is joint with my adviser Dyan S. Small and
each chapter’s contributors are appropriately marked at the beginning of the chapter
and project-specific acknowledgments are appropriately marked at the close of each
chapter.
Chapter II
Here, I write about the work I did in stepped-wedge cluster-randomized experiments
in which all clusters start out in the control and then clusters are randomized to
cross over to the treatment at staggered time. I investigated statistical properties of
the stepped-wedge design following the parametric mixed model approach proposed
by Hussey and Hughes in 2007. I found that testing for the treatment effect is
generally sensitive to specification of the parametric model. For instance, if one
fails to account for cluster-by-time interactions present in the data, the Type I error
rate is severely inflated. My collaborators and I developed a more robust and efficient
strategy-randomization inference as a unified framework to test for constant treatment
effects with guaranteed Type I error rate and satisfying power. The proposed method
was applied to the Burkina Faso CBHI dataset to study the financial benefits of
community-based health insurance (CBHI) schemes. We concluded that the insurance
had limited effects on reducing the likelihood of low to moderate levels of catastrophic
health expenditure, but substantially reduced the likelihood of extremely high health
2
expenditure that exceeds half of a person’s monthly income.
Chapter III
One-directional change of treatment status is a very strict rule for treatment as-
signment and randomized experiments are not always ethical and realistic to be
implemented. For the majority of existing observational data sets in the fields of
epidemiology, treatments, like prescriptions of a drug, are observed to switch sta-
tuses in unequal-spaced time intervals. Epidemiologic designs such as the cohort
study have been extensively studied to examine causal effects of such treatment using
individual-level data, yet can be biased if there are unmeasured competing risk fac-
tors. As a response, my collaborators and I proposed a hybrid ecologic-epidemiologic
design called the trend-in-trend (TT) design utilizing a strong time-trend in exposure.
Rather than comparing exposed vs. unexposed persons, the TT design derives causal
estimates by examining time-trends in outcome as a function of time-trends in expo-
sure across strata with different time-trends in exposure. We gave a mathematical
derivation of using aggregated data that are covariates-free to infer individual-level
causality. We reported a simulation study illustrating that the odds ratio estimated
using the TT method is much less biased than that estimated using cohort meth-
ods when there is unmeasured confounding. Finally, we applied the TT method to
healthcare data to reproduce the known positive association between rofecoxib and
acute myocardial infarction (AMI), and two presumably null associations: rofecoxib
and severe hypoglycemia, and rofecoxib and bone fracture.
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Chapter IV
The inference part of the TT design inspired me and my collaborators to think about
developing corresponding a sequential testing methodology. Sequential testing meth-
ods are powerful tools that facilitate early termination of a newly introduced drug
when the drug exceeds the pre-assumed adverse event rate. However, all the existing
sequential testing methods in observational settings rely heavily on the unstable as-
sumption of no unmeasured confounding. Because electronic health records are not,
in general, collected for scientific purposes, the no unmeasured confounding assump-
tion is unlikely to hold. We generalized the standard sequential likelihood ratio test
to trend-in-trend design settings that utilizes time trends in exposure prevalence and
accounts for both measured and unmeasured confounding under certain assumptions.
As the log likelihood ratio of the TT design does not have known asymptotic distri-
bution, we approximated the critical value using a Monte Carlo simulation method
involving α-spending approaches. The performance of the proposed approach is ex-
amined and compared to other approaches using simulation studies. We showed that
the results obtained by the existing methods may be misleading with an inflated Type
I error rate in the presence of unmeasured confounding while the proposed method
provides valid results.
Chapter V
While working on projects involving exploring discrete time-varying treatments, I
realized that in many real world data sets, it is more reasonable to assume that
the underlying processes are time-continuous processes, and that are only observed
at discrete time points. In particular, most cross-sectional and pooled panel data
that the Mendelian randomization is applied to are actually discrete snapshots of
dynamic processes, in which the outcome, the exposure, and covariates exhibit non-
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negligible serial correlations, and the outcome is an important determinant of future
exposure levels either directly or indirectly through other unmeasured factors. When
observations are inherently dynamic, conclusions from the Mendelian randomization
are hard to be interpreted. Even worse is that the conventional exclusion restriction
assumption, which is crucial for the validity of causal estimates is ungrounded so
that estimators derived based on static analysis could be severely biased from what
they were intended to estimate. We are therefore motivated to take a mechanistic
view by modeling reactions among variables using stochastic differential equations.
We show that discrete observations of a s time-continuous process generally obscure
the underlying local independence between the outcome and the instrument. Hence,
applying the Mendelian Randomization to discrete observational data without explicit
time justification, could give insensible conclusions.
5
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Randomization Inference for Stepped-wedge
Cluster-Randomized Trials: an Application to
Community-based Health Insurance
Abstract
National health insurance schemes are generally impractical in low-income countries
due to limited resources and low organizational capacity. In response to such obsta-
cles, community-based health insurance (CBHI) schemes have emerged over the past
20 years. CBHIs are designed to reduce the financial burden generated by unantici-
pated treatment cost among individuals falling sick, and thus are expected to make
health care more affordable. In this paper, we investigate whether CBHI schemes
effectively protect individuals against large financial shocks using a stepped-wedge
cluster-randomized design on data from a CBHI program rolled out in rural Burk-
ina Faso. We investigate statistical properties of the stepped-wedge design following
the parametric mixed model approach proposed by Hussey and Hughes in 2007. We
find that testing for the treatment effect is generally sensitive to specification of the
∗Joint work with Gunther Fink, Paul Jacob Robyn, Dylan Small
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parametric model. For instance, if we fail to account for cluster-by-time interactions
present in the data, the Type I error rate is severely inflated. We develop a more
robust and efficient strategy – randomization inference. We demonstrate how to ap-
ply randomization inference to test for constant treatment effects and discuss test
statistics suitable for the stepped-wedge design. Randomization inference guarantees
a valid Type I error rate; simulation studies show that randomization inference test
statistics also have power that is comparable to the currently used procedures that do
not guarantee a valid Type I error rate. Finally, we apply our proposed method to the
Burkina Faso CBHI dataset. We conclude that the insurance had limited effects on
reducing the likelihood of low to moderate levels of catastrophic health expenditure,
but substantially reduced the likelihood of extremely high health expenditure that
exceeds half of a person’s monthly income.
2.1 Introduction and Motivation
Community-based health insurance
The design of adequate health financing systems in low-income countries is a sub-
ject of significant debate. Due to low or modest economic growth, limited public tax
resources, and low organizational capacity, national health insurance schemes are gen-
erally impractical. In response to such obstacles, community-based health insurance
(CBHI) schemes, which are comparatively easier to set up, have emerged over the
past 20 years (Asenso-Okyere et al., 1997; De Allegri et al., 2006; Devadasan et al.,
2006; Ekman, 2004; Wang et al., 2009).
CBHI schemes are micro-insurance schemes that are voluntary, not-for-profit health
insurance schemes organized at the community level. Under CBHI schemes, members
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of a community, often defined by geographical proximity or through employment-
based relationships, pool resources in order to provide support for covering health
expenditure (Robyn et al., 2012). CBHI schemes seek to reduce the financial bur-
den generated by unanticipated treatment cost among individuals falling sick and are
thus expected to make health care more affordable. A natural question that emerges
then is: do CBHI schemes work as intended and in fact enhance universal financial
protection?
We consider a study of a CBHI program in rural Burkina Faso that was imple-
mented by the Ministry of Health and Nouna Health Research Center in the Nouna
District using a stepped-wedge cluster-randomized trial (Fink et al., 2013). We dis-
cuss properties of stepped-wedge cluster-randomized trials, problems with the cur-
rently used analysis methods for stepped-wedge cluster randomized trials, present
solutions to these problems and analyze the study of the CBHI program in Burkina
Faso.
Stepped-wedge cluster-randomized trials
A stepped-wedge cluster-randomized trial is a one-way crossover trial in which all
clusters start out in the control and then clusters are randomized to cross over to the
treatment at staggered times (Hall et al., 1987; Hussey and Hughes, 2007). Figure
2.1 illustrates the treatment schedule for a stepped-wedge trial; the name ”stepped-
wedge” refers to the series of steps of the treatment schedule, which results in a wedge
shape.
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Figure 2.1: Illustration of a stepped-wedge design where different groups of clusters
switch from control to treatment during different calendar periods.
The stepped-wedge design has been gaining popularity in recent years because of
a number of attractive features (Mdege et al., 2011). First, the stepped-wedge design
is useful for settings in which limited resources or geographical constraints make it
financially or logistically difficult to start the intervention in many clusters at once
(e.g., (Brown and Lilford, 2006; Hall et al., 1987; Mdege et al., 2011; Moulton et al.,
2007)). For example, in a parallel design (randomize half the clusters to treatment
during during single calendar period) or a traditional crossover design (randomize half
the clusters to treatment at baseline and then switch these clusters to control and
the other clusters to treatment midway through the trial), the intervention must be
implemented in half of clusters simultaneously, while the stepped-wedge design allows
researchers to implement the intervention in a smaller fraction of clusters during each
calendar period (Hussey and Hughes, 2007). Second, the stepped-wedge design (as
with a traditional crossover design) allows clusters to serve as their own controls,
which increases power when there are substantial cluster effects (Woertman et al.,
2013). The stepped-wedge design differs from a traditional crossover design, however,
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in that the crossovers are only in one direction; in particular, the intervention is never
removed once it has been implemented (at least over the course of the trial). Third,
because all clusters receive the treatment by the end of the trial and a cluster is never
withdrawn from receiving the treatment, the stepped-wedge design is particularly
useful for settings in which it would not be ethical, healthy or practical to withdraw
the treatment or in which it would be difficult for participants to quickly revert to
their pretreatment condition quickly after the withdrawal (Rhoda et al., 2011). The
stepped-wedge design is also useful for evaluating the population-level impact of an
intervention that has been shown to be effective in an individually randomized trial
or for which there is a majority opinion that the intervention will be effective so that
equipoise does not exist (Hussey and Hughes, 2007).
All these features made the stepped-wedge design ideal for studying the benefits
of the CBHI program in Burkina Faso. Because the CBHI program was expected to
confer benefits, every village in the study area wanted to be enrolled in the program
at the early stage. However, it takes time to scale up the program, so the CBHI
management team and the health district had no option but to rollout the program
in a progressive manner. The stepped-wedge design allowed the program to be rolled
out in a fair manner and the effect of the program to be studied through a randomized
trial. The stepped-wedge nature of the trial also helped to alleviate the spillover effect,
as the incentive to migrate to a different area just to benefit from the intervention
was counterbalanced by the fact that this very same intervention was going to be
implemented in the entire study area within the next few years.
Analysis Methods
In line with the increasing interest in employing and implementing the stepped-wedge
design, a handful of pivotal articles on testing intervention effects, sample size calcula-
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tions, and analytical methods for continuous or dichotomous outcomes have emerged
in the literature (e.g.,(Dimairo et al., 2011; Hussey and Hughes, 2007; Moulton et al.,
2007; Woertman et al., 2013)). Most of them have adopted the linear mixed model
approach proposed by Hussey and Hughes (2007).
Hussey and Hughes (2007) considered the linear mixed model:
Yijk = µ+ αi + βj + Zijθ + eijk, (2.1)
where Yijk is the observed response corresponding to individual k during calendar
period j from cluster i and Zij denotes whether cluster i has been assigned the
treatment by calendar period j. αi is a random effect for cluster i such that αi are
iid N(0, τ 2), βj is a fixed effect corresponding to time interval j (j in 1, . . . , T − 1,
βT = 0 for identifiability), θ is the treatment effect and eijk are individual, time period
specific effects that are assumed to be iid N(0, σ2e) and independent of αi.
One possible violation of assumptions in the linear mixed model (2.1) is the exis-
tence of cluster-by-time interactions, which are prevalent in a number of settings. For
example, cluster-by-time interactions were a concern in a recent proposal for using
the stepped-wedge design to study a vaccine for Ebola while the Ebola epidemic was
going on, because the Ebola epidemic, like other pandemics, was spreading from place
to place over time (Bellan et al., 2015; van der Tweel and van der Graaf, 2013). In the
CBHI study we are considering, cluster-by-time interactions are a concern because
the clusters are communities that are affected by different local economic and political
developments.
From a statistical point of view, adding an interaction term would increase the
correlation among observations within the same cluster and time period, therefore
changing the structure of the covariance matrix. Consequently, a larger sample size
would be required to achieve sufficient statistical power and, even worse, lead to
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invalid levels if the testing procedure is not chosen carefully.
Including all cluster-by-time interactions into the model as fixed effects would
make the treatment effect unidentifiable. Hussey and Hughes (2007) proposed one
strategy to deal with cluster-by-time interactions and still be able to estimate the
treatment effect: create strata of clusters with similar expected time trends and then
include stratum-by-time interaction as a factor in the model. This strategy requires
some knowledge of the expected time trends before the trial and runs the risk of
overfitting if interactions do not exist or are negligible. Without strong a priori
knowledge of the pattern of cluster-by-time interactions, a better approach is needed
to gauge the treatment effect than either excluding cluster-by-time interactions or
including a specific pattern of them.
Randomization inference
In this paper, we develop another approach for the analysis of stepped-wedge cluster-
randomized trials that accounts for potential cluster-by-time interactions – random-
ization inference. In randomization inference as developed by Fisher (1935), hypothe-
ses are tested using only the assumption that the randomization has been properly
carried out. Fisher said that randomization inference is ”reasoned basis for infer-
ence” because it uses only the physical act of randomization as a basis for inference,
and is exact and distribution-free. Tukey (1993) said that randomization inference
is the ”platinum standard” inference. For discussion and examples of randomization
inference, see Welch (1937); Raz (1990); Gail et al. (1996); Braun and Feng (2001);
Rosenbaum (a,b); Greevy et al. (2004); Ho and Imai (2006); Small et al. (2008);
Hansen and Bowers (2009).
Randomization inference can be applied to any test statistic of treatment effects.
Here we consider Wald test statistics based on the model (2.1) or other generalized
12
linear mixed models. Because the randomization procedure adds an extra layer of
security to the inference, the Type I error rate is valid even if parametric models for
responses are misspecified such as failing to account for cluster-by-time interactions.
We contribute to the literature by applying randomization inference to stepped-
wedge cluster-randomized trials. We build a unified framework to develop the ran-
domization distribution for any test statistic, which can be used to calculate p-values
and construct confidence intervals. Regarding our specific question, to what extent
do CBHI schemes enhance universal financial protection, we use the data from the
Burkina Faso study (Fink et al., 2013) to examine whether CBHI schemes help to
reduce the likelihood of catastrophic health expenditure. Our final results show that
the insurance had limited effects on reducing the likelihood of low to moderate lev-
els of catastrophic health expenditure, but substantially reduced the likelihood of
extremely high health expenditure that exceeds half of a person’s monthly income.
The outline of our paper is as follows. In Section 2, we introduce the potential
outcomes notation and set up that will be used throughout the paper. In Section 3,
we discuss consequences of failing to consider cluster-by-time interactions. In Section
4, we develop our randomization inference approach for the stepped-wedge design.
In Section 5, we conduct simulation studies comparing the randomization inference
approach to other analytical approaches for the stepped-wedge design. In Section 6,
we apply randomization inference for stepped-wedge trials to a study of a community-
based insurance program in rural Burkina Faso(Fink et al., 2013; Robyn et al., 2012).
In Section 7, we provide a summary.
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2.2 Notation and Set Up
There are I clusters, T calendar periods, and nij individuals sampled from cluster i
during calendar period j. N =
∑I
i
∑T
j nij is the total number of observations in the
study design. Let ijk index individual k in cluster i during calendar period j. An
individual might be sampled at multiple time points; the indices k = 1, . . . , nij are
time specific so that the same individual might have index k and k′ 6= k at different
times. During calendar period j, mj clusters are randomized to start treatment, where
m1 + · · ·+mT = I, so that each cluster eventually starts treatment. m1,m2, . . . ,mT
are prespecified before the start of the trial. Let Zij be the treatment corresponding
to cluster i during calendar period j, where Zij = 1 for the active treatment and 0
for the control. Since the trial is cluster-randomized, we index the treatment status
for clusters rather than individuals. Let Z be the vector of all treatment assignments,
Z = (Z11, Z12, . . . , ZIT ). Write Ω for the set containing |Ω| =
(
I
m1,...,mT
)
possible values
z of Z. Let Yijk be the observed response and Y be the vector of all observed responses,
Y = (Y111, Y112, . . . , YITnIT ). In case of a possible lag between the time of treatment
assignments and the time that responses are observed, we assume that if individual k
in cluster i enters the trial during calendar period j, so is assigned treatment Zij, then
that individual will continue to receive treatment Zij until response Yijk is recorded.
Each individual has a (row) vector of pretreatment covariates Xijk. X is the matrix
whose rows are Xijk.
We define the causal effect of interest under the potential outcomes framework.
We extend the notation of Neyman (1990) and Rubin (1974a) by representing each
potential outcome as a function of the vector of all treatment assignments z (Rosen-
baum, 2007). Write Y
(z)
ijk the response that the kth individual in cluster i during
calendar period j would have if the treatment assignment Z = z for z ∈ Ω. Y (z)ijk indi-
cates that each individual has |Ω| possible outcomes, only one of which is observed,
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namely Y
(Z)
ijk . Fisher’s sharp null hypothesis of no-treatment effect says that every
unit would exhibit the same response under all treatment assignments, Y
(z)
ijk = Y
(z′)
ijk
for all z, z′ ∈ Ω. Under the alternative hypothesis, observed outcomes may exhibit
arbitrary dependence.
We let F = 〈Y ,X〉, where Y is the unobserved array with N rows and |Ω| columns
having entries Y
(z)
ijk . F does not change as the treatment assignments, Z, change,
whereas Y is a function of F and Z so may change with Z. To employ the cluster-
randomized inference, as shown in Section 4, we assume the following assumptions
hold for F :
Assumption I: (a) there are no hidden variations of treatments and (b) Y
(z)
ijk = Y
(z′)
ijk
whenever zij = z
′
ij. Assumption I(a) is part of the Stable Unit Treatment Value
Assumption (Rubin, 1980; Imbens and Rubin, 2015) and says that an individual
receiving level z of the treatment cannot receive different forms of the treatment which
have different effects. The assumption is implicit in the notation Y
(z)
ijk which says that
there is a single potential outcome for level z of the treatment. Assumption I(b)
asserts that the potential outcomes would not be affected by treatment assignments
in other clusters or subjects in different clusters do not interfere. Note that this
assumption still allows for the possibility that units within a cluster at a given time
interfere with each other. Assumption I(b) can be seen as a relaxation of the usual
no interference part of the stable unit treatment value assumption (SUTVA) in the
sense that a group of concentrated individuals are allowed to interfere with each other
at a given time but interference is not allowed between groups or time points. This
assumption also implies no carry-over effect, that is, a previous treatment for one
subject does not affect later responses of this same subject and also treatments for
other subjects in the same cluster at previous times do not affect the response of the
given subject at this time.
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Assumption II: Pr(Z = z|F) = 1|Ω| =
1
( Im1,...,mT )
. This assumption says that
the clusters are randomly assigned as to when to start treatment according to the
stepped-wedge design and the conditional distribution of treatment assignments given
the potential responses and covariates is a fixed known constant.This assumption
guarantees that tests derived solely from the randomization have the correct level
whether or not potential responses within the same cluster are subject to interference
(Fisher, 1935; Welch, 1937).
Assumption III: If z and z′ are the same except that zij = 1 while z
′
ij = 0, then
Y
(z)
ijk −Y
(z′)
ijk = θ. This assumption implies that the treatment effect is constant across
population and over time. By removing the treatment effect from the whole cluster
during a calendar period, the observed responses would be the same as if there were
no treatments assigned. This constant effect θ is the causal effect of interest.
2.3 The Importance of Cluster-by-Time Interac-
tions
To motivate the need for accounting for cluster-by-time interactions, we assume that
Yijk is generated by the model
Yijk = µ+ αi + βj + γij + Zijθ + eijk (2.2)
For simplicity, we assume the eijk are independent but correlation among the eijk (as
might arise if individuals are observed multiple times) can be accommodated.
Both models (1.1) and (3.1) are observed data models that are consistent with
Assumptions I and II. Compared to the model (2.1), the model (2.2) has an additional
term γij that accounts for cluster-by-time interactions. γij’s are assumed to be iid
N(0, η2) and independent of α and e. Using matrix notation, the model (2.2) can be
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rewritten as
Y ∼ N(MΓ,Σ = σ2I + τ 2A+ η2B) (2.3)
where Y = (Y111, . . . , Y112, . . . , YITnIT ), Γ = (µ, β1, . . . , βT , θ)
T , and M is the N×(T+
2) design matrix. Let Yp denote the pth element in the vector Y which corresponds
to a value of ijk, then Mpq = 1 if (1) q = 1 or (2) 2 ≤ j ≤ T + 1 and Yp is observed
during calendar period q − 1 or (3) q = T + 2 and Yp is both observed and treated.
Mpq = 0 otherwise. A and B are symmetric positive definite matrices corresponding
to cluster and cluster-by-time interactions, respectively:
A = diag(1n1.1
T
n1.
, . . . ,1nI.1
T
nI.
) (2.4)
B = diag(1n111
T
n11
,1n121
T
n12
, . . . ,1nIT 1
T
nIT
) (2.5)
where 1n1 denote a column vector of 1’s with length n1 and ni. =
∑T
j=1 nij is the size
of cluster i.
Given σ2, τ 2, η2, the covariance matrix Σ is known. The best linear unbiased esti-
mator of Γ is the Generalized Least Squares (GLS) estimator, which asymptotically
has a normal distribution.
Γ̂GLS = (M
′Σ−1M)−1M ′Σ−1Y (2.6)
Γ̂GLS
d−→ N(Γ, (M ′Σ−1M)−1) (2.7)
If σ2, τ 2, η2 are not known, an implementable version of the GLS estimator is the
Feasible Generalized Least Squares (FGLS) estimator, which requires a consistent
estimate of Σ, say Σ̂.
Γ̂FGLS = (M
′Σ̂−1M)−1M ′Σ̂−1Y (2.8)
One common strategy to find a consistent estimate Σ̂ is to start by finding Γ̂OLS or
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another consistent (but inefficient) estimator, take the residuals from OLS to build a
consistent estimator of the error covariance matrix Σ, update the FGLS estimation,
and then apply the same idea iteratively until the estimators vary less than some tol-
erance. Under regularity conditions, such a FGLS estimator has the same asymptotic
distribution as a GLS estimator.
Γ̂FGLS
d−→ N(Γ, (M ′Σ−1M)−1) (2.9)
For finite samples, the estimated covariance matrix of Γ̂FGLS is
V̂ ar[Γ̂] = (M ′Σ̂−1M)−1 (2.10)
which converges to the asymptotic covariance matrix (M ′Σ−1M)−1 given that Σ̂ con-
verges to Σ (Greene, 2003).
However, it is not always the case that we can find a consistent estimator of the
covariance matrix Σ. The convergence of Σ̂ to Σ relies on the correct specification
of matrix structure and normality assumptions (Jacqmin-Gadda et al., 2007). In the
process of iteratively computing Σ̂, any deviation from the correct model would lead to
an inconsistent version of Σ̂. In particular, if we failed to account for cluster-by-time
interactions in the case of stepped-wedge cluster-randomized trials, we would specify
the structure of covariance matrix in a different form from the actual covariance
matrix, i.e., we would assume the consistent estimate of Σ to be Σ̂ = σ̂2I+ τ̂ 2A while
the actual covariance matrix is in the form of Σ = σ2I + τ 2A + η2B. Since B is a
positive definite matrix as defined in 2.5, no values of σ̂2 and τ̂ 2 would satisfy the
equation σ̂2I + τ̂ 2A = σ2I + τ 2A + η2B. Consequently, any computed Σ̂ would be
inconsistent, even if it maximizes the likelihood. Therefore, inferences based on Σ̂
using the asymptotic distribution would be invalid.
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We use a simulation study to examine this difference between the estimated vari-
ance of the treatment effect, which is the last diagonal element of Σ̂ and the Monte
Carlo simulation of the true variance, which is the last diagonal element of Σ. R code
for the simulation is available in supplementary materials.
In the simulation, I and T are set to be 30 and 4, respectively. All clusters start
with control at T = 1 and during each calendar period starting from T =2, 10 clusters
in the control group are randomly selected to be assigned to treatment. All clusters
have equal size 100 and the true treatment effect θ = 0. The magnitude of clustering
is calibrated by the intracluster correlation coefficient (ICC), which is the proportion
of the total variation explained by the respective blocking factor. In particular, the
correlation between two randomly selected observations in the same cluster is:
ICCI =
τ 2
τ 2 + η2 + σ2
(2.11)
The correlation between two randomly selected observations in the same cluster and
during the same calendar period is:
ICCIT =
τ 2 + η2
τ 2 + η2 + σ2
(2.12)
As a result, the magnitude of interaction can be calibrated by ICCIT − ICCI =
η2
τ2+η2+σ2
, which is the extra correlation from the same cluster and calendar period
compared to just the cluster.
In Figure 2.2, we compare the distribution of estimated variances V̂ ar[θ̂] over
10000 simulations with the Monte Carlo simulation of the true variance. When there
are no cluster-by-time interactions, i.e., the model (2.1) is correctly specified, the left
plot in Figure 2.2 indicates that the distribution of V̂ ar[θ̂] is centered around the
true variance, marked by the red vertical line. However, when interactions do exist,
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the estimated variances are far off the true variance. The right plot describes two
scenarios with different magnitudes of interactions. Neither of the distributions is
close to the true variance.
(a) No cluster-by-time interactions
(b) With cluster-by-time Interactions
Figure 2.2: Comparison of estimated and true variances of the treatment effect in
different settings of cluster-by-time interactions. In (a), there are no cluster-by-time
interactions, ICCI :=
τ2
τ2+σ2
= 0.02. In (b), there are cluster-by-time interactions,
ICCI :=
τ2
τ2+σ2
= 0.02, ICCIT :=
τ2+η2
τ2+η2+σ2
= 0.025(upper) and 0.04 (lower).
Table 2.1 gives a more detailed summary of the estimated treatment effect θ̂ given
by the FGLS estimator when the cluster-by-time interactions are not included in the
model. As shown by column E[θ̂], θ̂ is consistent in all settings. When there are
no cluster-by-time interactions as shown by the first two rows, the average of the
estimated variances E(V̂ ar[θ̂]) is almost the same as the Monte Carlo simulation
of the true variance V ar[θ̂]. But this is not the case when the interaction term γ
is nonzero. The last column SD(V̂ ar[θ̂]) describes the dispersion of the estimated
variances, which is of a much smaller order than its average.
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dim(M) α γ ε E[θ̂] V ar[θ̂] E(V̂ ar[θ̂]) SD(V̂ ar[θ̂])
N(0,1) Zero N(0,49) -0.0031 0.0544 0.0548 0.0012
I=30 N(0,1) Zero 7/
√
3t(3) -3.4e−5 0.0544 0.0545 0.0080
N(0,1) N(0,.25) N(0,48.75) -0.0008 0.0816 0.0549 0.0012
T=4 N(0,1) N(0,.5) N(0,48.5) -0.0008 0.1083 0.0550 0.0012
N(0,1) N(0,1) N(0,48) -0.0008 0.1626 0.0552 0.0011
Table 2.1: Properties of the estimated treatment effect given by the Feasible Gener-
alized Least Square estimator
The above simulation results show that fitting a linear mixed model for the
stepped-wedge design while ignoring cluster-by-time interactions can lead to severely
wrong standard errors, and this leads to poor control of Type I error rate, as shown
by Table 2.2.
dim(M) α γ ε ICCI ICCIT Type I error
N(0,1) Zero N(0,49) 0.02 0.02 0.052
I= 30 N(0,1) Zero 7/
√
3t(3) 0.02 0.02 0.054
N(0,1) N(0,.25) N(0,48.75) 0.02 0.025 0.511
T=4 N(0,1) N(0,.5) N(0,48.5) 0.02 0.03 0.658
N(0,1) N(0,1) N(0,48) 0.02 0.04 0.756
Table 2.2: Type I error of linear mixed models not accounting for cluster-by-time
interactions
2.4 Randomization Inference for Stepped-Wedge
Cluster-Randomized Trials
We would like to develop a strategy that accounts for cluster-by-time interactions if
they exist. We will consider randomization inference. In randomization inference as
developed by Fisher (1935), hypotheses are tested using only the assumption that
the randomization has been properly carried out and randomization inference pro-
vides exact, distribution-free inferences. The significance level is always guaranteed
21
regardless of the underlying mechanism that generates the data.
A General Setup
There are I clusters and T calendar periods. At time t, mt clusters are randomized
to start treatment, where m1 + · · · + mT = I, so that each cluster eventually starts
treatment. Collect all possible values z of the treatment assignments Z in a set Ω,
|Ω| =
(
I
m1,...,mT
)
. Because random numbers are used to assign which clusters start
treatment at which times, P (Z = z) = 1/|Ω| for each z ∈ Ω.
Let e be a function of F = 〈Y ,X〉 and let t(Z, e,X) be any function of Z, e,X.
Because e and X are functions of F and randomization ensures P (Z|F) = 1/|Ω|, it
follows that for all v,
P (t(Z, e,X) ≥ v|F) = |{z ∈ Ω : t(z, e,X) ≥ v}|
|Ω|
, (2.13)
which is the randomization distribution of t(Z, e,X). In words, given F , the chance
that t(Z, e,X) ≥ v is simply the proportion of treatment assignments z ∈ Ω such that
t(Z, e,X) ≥ v. Moreover, (2.13) is the distribution of t(Z, e,X) given F no matter
what process produced F . Fisher’s (1935) description of randomization inference as
the “reasoned basis for inference” refers to the fact that randomization creates the
distribution (2.13) for every function e of F without further assumptions.
Test of No Effect
The sharp null hypothesis of no effect asserts that the response of each individual is
unchanged by receiving the treatment, H0 : ∀z, z′ ∈ Ω, Y (z)ijk = Y
(z′)
ijk for i = 1, . . . , I,
t = 1, . . . , T , k = 1, . . . , nit, i.e., Y
(z) = Y(z
′). If H0 were true, randomization would
label clusters treated or control but the observed outcomes would be unchanged. If
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H0 were true, the observed response Y
(Z) would equal Y(0), a special case where all
clusters are under control. Thus, under the null hypothesis of no treatment effect,
the randomization distribution of t(Z,Y,X) = t(Z,Y(0),X) would be given by (2.13)
with e = Y(0), where both t(Z,Y(0),X) and its null distribution (2.13) would be
calculated from the observed data when H0 were true. For instance, in completely
randomized experiments, Welch (1937) tested the null hypothesis of no effect using
the randomization distribution of a test statistic suggested by analysis of variance
and Raz (1990) used the randomization distribution of a test statistic that adjusted
for X using a data smoother.
Test of Constant Treatment Effect
The above method can be directly extended to test for constant treatment effect
H0 : θ = θ0 v.s. H1 : θ = θ1
Under the null hypothesis of θ = θ0, Y
(0) = Y − Zθ0. If e = Y(0), t(Z, e,X) =
t(Z,Y − Zθ0,X) = t′(Z,Y,X), where t′ is a function on Z,Y,X. This is to say
t′(Z,Y,X) would also have the randomization distribution given by (2.13).
Because of the randomization procedure, any function t on Z,Y(0),X is a valid
test statistic with the Type I error controlled by the prespecified significance level.
However, it does not mean that any arbitrarily chosen t is a good test statistic. We
need to consider power. In the next section, we will discuss test statistics suitable for
stepped-wedge cluster-randomized experiments.
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Wald Randomization Test
A natural choice of t is the Wald statistic based on the maximum likelihood estimation
of the treatment effect under the model (2.1) or (2.2). Under the null hypothesis H0 :
θ = θ0, Y − Zθ0 = Y(0) = e. The maximum likelihood estimator of L(θ|Z,Y,X) =
L(θ|Z, e + Zθ0,X) is a function on Z, e, and X. t(Z, e,X) can be chosen as the Wald
statistic of the null hypothesis H0 : θ = θ0 over the alternate hypothesis H1 : θ 6= θ0
t(Z, e,X) =
(θ̂ − θ0)2
V̂ ar(θ̂)
(2.14)
Instead of using its asymptotic distribution, which is a χ2 distribution under the
null hypothesis, the level is calculated using the randomization distribution given by
(2.13). We can also investigate the power by randomly generating numerous data sets
under a pre-specific alternative hypothesis. For each of these data sets, randomization
inference is carried out and the evidence for or against the null hypothesis is recorded.
The Wald randomization test is applicable to a wide range of parametric models
corresponding to different distributions of observed outcomes and can be implemented
using standard functions in R, such as lmer() in the lme4 package for linear mixed
models, glm() for generalized linear models, and censReg() in the censReg package
for censored regression models.
Other Randomization Tests
Instead of calculating the maximum likelihood estimate and its standard deviation,
other test statistics are available for stepped-wedge cluster-randomized trials. For
example, because the design is essentially a two-way layout, we can first eliminate
row and column effects by estimating their values or using the median polish method if
robustness is a concern (Hoaglin et al., 1983). We then carry out the aligned rank test
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to compare the adjusted responses between clusters with different interventions (Sen,
1968). If responses have heavy-tailed distributions, we may consider test statistics
involving ranks to avoid bias caused by extreme values.
Covariates Adjustment
The discussion in Sections 4.2 and 4.3 make no use of the covariates, X, but it is
straightforward to incorporate them, with no change in the logic, see Rosenbaum
(a). Instead of letting e = Y(0), e could also be a function on X. For example, e
could be residuals when Y(0)is regressed on X by any method of regression. The
randomization distribution of t(Z, e,X) would still be given by (2.13).
2.5 Simulation Study
We use a simulation study to investigate the level and the power of the Wald test
statistic with usual asymptotic inference and with randomization inference in the
stepped-wedge design. For demonstration purpose, we assume responses are normal
and continuous. In all simulation settings, I = 30 and T = 4. When t = 0, all clusters
are in the control group. When t = 1, 10 out of 30 clusters are randomly selected
to receive treatment. When t = 2, 10 out of the remaining 20 untreated clusters
are randomly selected to receive treatment. When t = 3, all clusters are assigned to
treatment. Cluster sizes are randomly sampled between 1000 and 2000 and fixed over
time. The true treatment effect θ0 is set to be 0 and the power is calculated under
the alternative θ1 = .25, .5, 1, 1.5, 2. ICCI =
τ2
τ2+η2+σ2
is the intracluster correlation
coefficient corresponding to clusters. ICCIT =
τ2+η2
τ2+η2+σ2
is the intracluster correlation
coefficient corresponding to both clusters and interactions. All numbers reported are
the average over 1000 sets of randomly simulated data set.
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We first examine the Type I error rate in several scenarios. Waldasy and Waldrand
are obtained under the model (2.1) with usual asymptotic inference and with ran-
domization inference. Wald∗asy and Wald
∗
rand are obtained under the model (2.2) with
usual asymptotic inference and with randomization inference.
α γ e Waldasy Waldrand Wald
∗
asy Wald
∗
rand
N(0,1) Zero N(0,49) .045 .061 .044 .061
N(0,1) Zero 7/
√
3t(3) .042 .055 .042 .054
N(0,1) Zero Cauchy .055 .050 .051 .053
N(0,1) N(0,1) N(0,48) .315 .055 .069 .059
N(0,1) N(0,1) 4
√
3t(3) .342 .051 .069 .054
N(0,1) N(0,1) Cauchy .056 .054 .063 .060
Table 2.3: Type I error rate of the Wald test statistic based on the asymptotic
distribution and the randomization distribution
It can be seen from Table 2.3 that both randomization procedures Waldrand and
Wald∗rand guarantee the correct Type I error rate in all settings. When the interaction
γ is zero, the Type I error rate is well-controlled by both tests with usual asymptotic
inference. However, when γ has a stand normal distribution, which leads to a small in-
tracluster correlation coefficient ICCIT = 0.04, the Type I error rate given by Waldasy
is inflated to .315 and .342 when e follows a normal and a t distributions, respectively.
The Wald∗asy test performs better than Waldasy as it incorporates cluster-by-time in-
teractions, but its Type I error rate is still slightly higher than its randomized version.
Such phenomenon disappears when e follows a Cauchy distribution. This might be
explained by the fact that the Cauchy distribution is so heavy-tailed that it dominates
the small interaction term γ.
We next examine power. According to results in Table 2.4, when there are no
cluster-by-time interactions, the randomization tests have comparable power with the
tests using the asymptotic distribution. When there are cluster-by-time interactions,
we ignore the power calculated from Waldasy and Wald
∗
asy as the level is no longer
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valid, but only focus on their randomized versions, which give sufficient power to
detect wrong values of the treatment effect.
θ1 α γ e ICCI ICCIT Waldasy Waldrand Wald∗asy Wald∗rand
.25 N(0,1) Zero N(0,49) .02 .02 . 254 .275 .254 .276
.5 N(0,1) Zero N(0,49) .02 .02 .723 .715 .721 .725
1 N(0,1) Zero N(0,49) .02 .02 .999 .999 .999 .999
1.5 N(0,1) Zero N(0,49) .02 .02 1 1 1 1
2 N(0,1) Zero N(0,49) .02 .02 1 1 1 1
.25 N(0,1) N(0,1) N(0,48) .02 .04 . 427 .096 .136 .108
.5 N(0,1) N(0,1) N(0,48) .02 .04 .636 .253 .335 .277
1 N(0,1) N(0,1) N(0,48) .02 .04 .941 .726 .798 .752
1.5 N(0,1) N(0,1) N(0,48) .02 .04 .999 .969 .982 .975
2 N(0,1) N(0,1) N(0,48) .02 .04 1 1 1 1
.25 N(0,1) Zero 7/
√
3t(3) .02 .02 .266 .272 .261 .280
.5 N(0,1) Zero 7/
√
3t(3) .02 .02 .751 .734 .740 .744
1 N(0,1) Zero 7/
√
3t(3) .02 .02 .998 .999 .998 .999
1.5 N(0,1) Zero 7/
√
3t(3) .02 .02 1 1 1 1
2 N(0,1) Zero 7/
√
3t(3) .02 .02 1 1 1 1
.25 N(0,1) N(0,1) 4
√
3t(3) .02 .04 .416 .107 .124 .115
.5 N(0,1) N(0,1) 4
√
3t(3) .02 .04 .630 .240 .310 .272
1 N(0,1) N(0,1) 4
√
3t(3) .02 .04 .942 .718 .786 .786
1.5 N(0,1) N(0,1) 4
√
3t(3) .02 .04 .999 .971 .999 .992
2 N(0,1) N(0,1) 4
√
3t(3) .02 .04 1 1 1 1
Table 2.4: Power of the Wald test statistic for linear mixed models based on the
asymptotic distribution and the randomization distribution
We also carry out a set of simulations for dichotomous outcomes, according to the
model
logit(E(Yijk)) = µ+ αi + βj + γij + Zijθ (2.15)
Results are summarized in Table 2.5, showing similar advantages of using ran-
domization inference for the stepped-wedge cluster-randomized trials.
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θ1 α γ e ICCI ICCIT Waldasy Waldrand Wald∗asy Wald∗rand
0 N(0,1) Zero N(0,49) .02 .02 .043 .051 .044 .051
.5 N(0,1) Zero N(0,49) .02 .02 .223 .208 .216 .195
1 N(0,1) Zero N(0,49) .02 .02 .791 .747 .773 .740
1.5 N(0,1) Zero N(0,49) .02 .02 1 .999 .998 .998
0 N(0,1) N(0,1) N(0,48) .02 .04 .217 .060 .091 .048
.5 N(0,1) N(0,1) N(0,48) .02 .04 .412 .172 .318 .159
1 N(0,1) N(0,1) N(0,48) .02 .04 .726 .448 .544 .377
1.5 N(0,1) N(0,1) N(0,48) .02 .04 .922 .681 .837 .572
Table 2.5: Power of the Wald test statistic for generalized linear mixed models based
on the asymptotic distribution and the randomization distribution
2.6 Application to Study of Community-Based Health
Insurance Program
Background
The Ministry of Health and Nouna Health Research Center in Nouna District, Burkina
Faso implemented a CBHI scheme from 2004 to 2006 that aimed to make health
care more affordable and to protect local communities from large health expenditure
shocks (Fink et al., 2013; Robyn et al., 2012). To allow for a proper evaluation, the
rollout of the program followed a stepped-wedge cluster-randomized design, enrolling
randomly selected communities in three phases. In order to investigate the effect of
CBHI schemes on household welfare, we follow Fink et al. (2013) to analyze the effect
of CBHI schemes on catastrophic expenditure.
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2.6.1 Data
The data we use is the Nouna Health and Demographic Surveillance Site (HDSS)
survey data collected from 2003 to 2008. Data from year 2003 are the baseline prior
to the intervention and data from years 2007 and 2008 are controls after the final
rollout phase. There are 48 areas in the health district and each of them is considered
a cluster. Due to residential mobility and migration, the study population is dynamic
with an attrition rate of 59% from 2003 to 2008. There are 59,905 records in total and
the number of individuals targeted by the insurance program in phase I, II, and III are
27,696, 14,292, and 17,917, respectively. Equal mean test indicates that these three
rollout groups have balanced covariates of age, gender, years of education, literacy,
religion, marital status, household size, and wealth index, see Table 4 in Fink et al.
(2013).
Since the primary objective of CBHI schemes is to protect individuals against large
financial shocks, we investigate the probabilities of facing health expenditure greater
than 5%, 10%, 15%, 25% and 50% of monthly income. The catastrophic expenditure
is a dichotomous outcome, which is coded as one if the total health expenditure is
greater than a certain percentage of the monthly income. For example, in the 2003
data suggest that about 10.4% of individuals faced health expenditure larger than 5%
of their monthly income in the sample, and 2.7% of individuals had to cover health
expenditure of more than half their monthly income. See Table 2.6 for a detailed
year-by-year summary of the data.
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Year Population Expenditure Cutoff
size ≥ 5% ≥10% ≥15% ≥25% ≥50%
2003 7796 814 610 460 347 207
2004 8619 1037 716 577 361 191
2005 6875 1402 977 742 519 311
2006 10712 925 576 481 306 224
2007 13784 1316 939 690 377 211
2008 12118 950 663 452 291 141
Table 2.6: Distribution of catastrophic expenditure over time, Nouna HDSS House-
hold Survey, 2003 – 2008.
Model
The models (2.1) and (2.2) assume the continuity of observed responses and the nor-
mality of random components. In our data, catastrophic health expenditure is binary
so we use the generalized linear mixed model and then apply the Wald randomiza-
tion test. In particular, we use Pijk to denote the probability of facing catastrophic
expenditure for individual k during calendar period j from cluster i, the observed
response Yijk follows the model
Yijk ∼ Bernoulli(Pijk) (2.16)
logit(Pijk) = µ+ αi + βj + Zijθ +X
T
ijkγ + eijk
where αi, βj, Zij, and θ are defined the same as in the model (2.1) and Xijk is a vector
of covariates that we adjust for, which are age, gender, years of education, literacy,
religion, marital status, household size, and wealth index. Because we have repeated
observations on people and there might be unmeasured covariates not included in
Xijk, eijk could be correlated for j ∈ {1, 2, . . . , T}. As a result, we include person-
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level random effects to allow for correlation between eijk and eij′k.
Results
We first investigate catastrophic expenditure that is greater than 5% of monthly in-
come. We use the function lmer() from the package lme4 to solve for the maximum
likelihood estimate of θ in (2.16), which has mean value -0.3966 and standard devia-
tion 0.0554. Hence, the Wald test statistic for the actual insurance rollout is 51.093
with p-value < 0.001, indicating that there is significant evidence that the CBHI in-
surance program helped to reduce the likelihood of facing health expenditure greater
than 5% of monthly income. We then carry out the Wald randomization test by
assuming that there was no such effect. The p-value given by (2.13) is 0.117, indicat-
ing that there is no strong evidence that insurance had an effect on the catastrophic
expenditure. We also consider an expanded version of the model (2.16) that includes
cluster-by-time interactions:
Yijk ∼ Bernoulli(Pijk) (2.17)
logit(Pijk) = µ+ αi + βj + γij + Zijθ +X
T
ijkγ + eijk
The Wald statistic based on this model for the actual insurance rollout is 2.229 with
p-value 0.135 and the Wald randomization test gives p-value 0.115.
We repeat the same analysis for expenditure cutoffs 10%, 15%, 25%, and 50%
and summarize results in Table 2.7. P-values in columns Waldasy and Waldrand are
obtained under the model (2.16) with usual asymptotic inference and with random-
ization inference. P-values in columns Wald∗asy and Wald
∗
rand are obtained under the
model (2.17) with usual asymptotic inference and with randomization inference.
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Expenditure p-value
cutoff Waldasy Waldrand Wald
∗
asy Wald
∗
rand
≥5% < .001 .117 .135 .115
≥10% < .001 .339 .351 .331
≥15% < .001 .431 .463 .427
≥25% < .001 .442 .422 .410
≥50% .009 .041 .014 .038
Table 2.7: CBHI’s impact on catastrophic health expenditure based on generalized
linear mixed models
Conclusion
Based on randomization inference that controls the Type I error rate properly, there
is no strong evidence that the CBHI program carried out in Nouna District, Burkina
Faso affected catastrophic expenditure that are defined to be greater than 5%, 10%,
15%, and 25% of monthly income. The CBHI program, however, conferred a large
benefit to people facing extremely high health expenditure that exceeds half of their
monthly income. We see discrepancy between results from the model (2.16) and the
model (2.17) using asymptotic inference. The model (2.16) would conclude that the
CBHI program substantially reduced the likelihood of all levels of catastrophic health
expenditure, but the model (2.17) would conclude so only for the 50% cutoff.
Table 2.7 suggests that conclusions given by the asymptotic inference and the ran-
domization inference are consistent only for the model (2.17), which is an indication
of the presence of cluster-by-time interactions. If we failed to consider the cluster-by-
time interactions, the standard asymptotic inference is likely to greatly overestimate
the protective effects of the insurance program
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2.7 Summary
There is a lack of literature on the theoretical aspects of analyzing the stepped-wedge
cluster-randomized trials. We focus on statistical properties of the stepped-wedge
design following the linear mixed model approach proposed by Hussey and Hughes
(Hussey and Hughes, 2007). Our simulations raise a red flag about using model-
based inference for stepped-wedge trials. Specifically, the results can be very sensitive
to model misspecification. As a result, bias can be introduced by cluster-by-time
interactions and any other violations of assumptions.
We thus propose a new approach to the analysis of stepped-wedge cluster-randomized
trials – using randomization inference to test for constant interventions. We introduce
a unified framework to develop the randomization distribution for any test statistic,
which can be used to calculate p-values and construct confidence intervals. Simula-
tions based on linear mixed models show that randomization inference always guar-
antees the valid Type I error rate and has power comparable to the usual asymptotic
inference.
We demonstrate our method using the Burkina Faso CBHI dataset to investi-
gate whether CBHI schemes protect individuals against large financial shocks. We
conclude that the insurance had limited effects on reducing the likelihood of low to
moderate levels of catastrophic health expenditure in the target areas, but substan-
tially benefited people facing extremely high health expenditure that exceeds half of
their monthly income.
We hope that this paper serves as a valuable contribution to the literature on
statistical properties of stepped-wedge cluster-randomized trials and its practical im-
plementation in health economics, education, public health and other fields in which
cluster-randomized trials are of interest. Our goal in this paper is to emphasize the
value of randomization inference for stepped-wedge cluster-randomized trials and pro-
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vide methods for implementing such randomization inference. With a strong belief
in a parametric model, one can make inferences and calculate power and sample size
based on asymptotic distributions but these inferences can be sensitive to the model;
randomization inference can deliver similar power while the inferences remain valid
regardless of whether the parametric model holds or not.
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The Trend-in-trend Design for Causal Inference
Abstract
Cohort studies can be biased by unmeasured confounding. We propose a hybrid
ecologic-epidemiologic design called the trend-in-trend design, which requires a strong
time-trend in exposure, but is unbiased unless there are unmeasured factors affecting
outcome for which there are time-trends in prevalence that are correlated with time-
trends in exposure across strata with different exposure trends. Thus, the conditions
under which the trend-in-trend study is biased are a subset of those under which a
cohort study is biased. The trend-in-trend design first divides the study population
into strata based on the cumulative probability of exposure (CPE) given covariates,
which effectively stratifies on time-trend in exposure, provided there is a trend. Next,
a covariates-free maximum likelihood model estimates the odds ratio (OR) using data
on exposure prevalence and outcome frequency within CPE strata, across multiple pe-
riods. In simulations, the trend-in-trend design produced ORs with negligible bias in
the presence of unmeasured confounding. In empiric applications, trend-in-trend re-
produced the known positive association between rofecoxib and myocardial infarction
∗Joint work with Sean Hennessy, Charles Leonard, Dylan Small
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(observed OR: 1.23, 95% confidence interval: 1.05, 1.44), and known null associations
between rofecoxib and severe hypoglycemia [OR = 1.09 (0.92, 1.28)] and non-vertebral
fracture [OR = 0.84 (0.64, 1.09)]. The trend-in-trend method may be useful in set-
tings where there is a strong time-trend in exposure, such as a newly-approved drug
or other medical intervention.
3.1 Introduction
Many important causal questions cannot be addressed through randomized trials be-
cause of ethical or practical reasons. Ecologic studies address causal questions by
examining time trends in exposure and outcome, but can be biased by co-occurring
trends in other factors affecting outcome (Cook et al., 1979). Epidemiologic designs
such as the cohort study can be biased if there are unmeasured determinants of expo-
sure that are associated with outcome (i.e., unmeasured confounders). In this paper,
we introduce a novel hybrid ecologic-epidemiologic design called the trend-in-trend
design. Rather than comparing exposed vs. unexposed persons, the trend-in-trend de-
sign examines time-trends in outcome as a function of time-trends in exposure across
strata with different time-trends in exposure. Intuitively, in a population stratified on
time-trends in exposure, an association between exposure time-trends and outcome
time-trends across strata should provide evidence for causation unless there are un-
measured factors affecting outcome for which there are time-trends in prevalence that
are correlated with time-trends in exposure across strata. Thus, the scenarios under
which a trend-in-trend study is susceptible to unmeasured confounding should be a
subset of those under which a cohort study is susceptible, making the trend-in-trend
design more resistant to unmeasured confounding. The trade-offs are that a trend-
in-trend study is feasible only when there is a strong time-trend in exposure, and a
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trend-in-trend study should have less statistical precision than a cohort study.
While novel, the trend-in-trend design is related to two established econometric
approaches. One is the difference-in-difference (DID) method (Lechner et al., 2011;
Meirik, 2008), as both address unmeasured confounding by examining within-group
changes and time-trends in outcome. However, unlike the DID method, the trend-
in-trend design estimates an individual-level causal parameter. In particular, the
trend-in-trend design yields the odds ratio (OR), which approximates the risk ratio
when the outcome is rare (Viera, 2008). The trend-in-trend method is also related to
the use of calendar time as an instrumental variable (IV) (Cain et al., 2009; Johnston
et al., 2008), and in fact the two are equivalent if only a single stratum is used in
the trend-in-trend design. However, use of calendar time as an IV can be biased by
any time-trend in the prevalence of an unmeasured factor that affects outcome. In
contrast, the trend-in-trend design is biased by such a trend only if the time-trend
in the unmeasured factor is correlated with the time-trends in exposure across strata
defined by factors associated with exposure. The trend-in-trend design therefore
relaxes the assumptions under which a calendar time IV study is valid.
In this paper, we first introduce the cumulative probability of exposure (CPE),
which is used to divide the population into strata with different exposure prevalences
and thus different time-trends in exposure, provided that an overall time-trend exists.
We then propose two reasonable models for individuals and subgroups respectively.
Under the assumptions that the outcome is rare, covariates are either time-invariant or
change randomly over time within person, and there are no time-trends in unmeasured
causal factors that are associated with time-trends in exposure across strata, we give
a mathematical derivation of the connection between individuals and subgroups and
a method to estimate the OR using group-level data. We then show mathematically
that this estimate is unbiased by both measured and unmeasured confounders. We
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report a simulation study illustrating that the OR estimated using the trend-in-trend
method is much less biased than that estimated using cohort methods when there is
unmeasured confounding by factor with no trend in prevalence. Finally, we apply the
trend-in-trend method to healthcare data to reproduce the known positive association
between rofecoxib and acute myocardial infarction (AMI) (Jüni et al., 2004), and two
presumably null associations: rofecoxib and severe hypoglycemia, and rofecoxib and
bone fractur (Vestergaard et al., 2006).
3.2 Method and Models
3.2.1 Stratification based on the Cumulative Probability of
Exposure (CPE)
The analysis of a trend-in-trend study involves two stages. In the first stage, we
estimate the CPE, which is the predicted probability of exposure over the entire study
period, based on variables other than exposure, outcome, and their potential effects.
In particular, suppose we observe a population in which each individual’s binary
exposure status over the study period is observed. We also observe a set of variables
that affect but are known from subject-area knowledge not to be affected by exposure,
such as age, sex, geographic residence, diagnoses, etc. We fit a logistic regression
model using these variables as independent variables, with the dependent variable
being exposure. The fitted value is the estimated CPE. Since the unit of analysis for
the CPE model is the individual, and covariates are treated as invariant, each subject
will be in the same CPE stratum for all observation periods. If, analogously to a new
user cohort study, subjects are required to be present for a baseline period prior to
the first opportunity for exposure, then the values for all variables in the CPE model
can be fixed at the first opportunity for exposure (e.g., drug approval). However,
38
many healthcare databases have high turnover rates, and restricting the study to
persons with sufficient baseline period prior to the first opportunity for exposure
may drastically reduce available sample size. In such a situation, one can allow the
value of CPE variables that require time to ascertain (e.g., appearance of diagnoses)
to be determined by data observed during the study period, provided that subject-
area knowledge can rule out the possibility that exposure status affected any CPE
variable. For an exposure with an overall time-trend in prevalence, intuition tells us
that the magnitude of the trend should vary across strata defined by the CPE. The
CPE is similar to the propensity score (Rosenbaum and Rubin, 1983), since both
predict exposure, but differs from it in that the propensity score is used to balance
observed covariates across exposure groups, while the CPE is used to identify strata
with different time-trends in exposure. It may also be possible to directly model the
trend itself rather than the CPE. The second stage analysis, described below, applies
to any population stratified on time-trend in exposure prevalence.
3.2.2 Models in the Trend-in-Trend Design
To derive a quantitative estimate of a causal effect, we propose two models of out-
comes. One model is defined for each subject at each time point to account for
covariates heterogeneity across population and time trends of outcome. The other
one is specified at the population level at each time point, which depicts the mean
outcome among those subjects within the same subgroup. We assume that the study
population consists of N individuals and there are T time periods. Let X ti denote the
vector of covariates associated i with individual t at time period , which represents
intrinsic characteristics that might influence a particular exposure and/or outcome.
X ti can be either observed, unobserved, or partially observed. X
t
i is assumed to follow
a distribution F across the population. Zti and Y
t
i are exposure and outcome variables
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for individual i at time period t. G is the index for CPE strata.
3.2.2.1 Subject-Specific Model
The conditional expected outcomes are assumed to satisfy
h(µti) = β0 + β1Z
t
i + β2t+ γ
TX ti (3.1)
where h is the link function. The subject-specific model is a special case of the
generalized linear mixed model with exposure and time period being the fixed effects
and the covariates for an individual (some of which may be unobserved) represented
as random effects (Zeger et al., 1988). Because the trend-in-trend design is intended to
estimate the instantaneous risk of an exposure, only Zti instead of the past treatment
history Z1:Ti is considered as a predictor of the the conditional expected outcome.
The coefficient β1 for exposure has a causal interpretation at the individual level. It
is also the logarithm of the OR when both exposure and outcome are binary, and the
function h is logit.
When unmeasured confounding does not exist, i.e., X ti can be fully observed, it is
valid to estimate all coefficients in equation (1) using individual-level data. For ex-
ample, the cohort design utilizes information about every unit in a group to examine
associations with exposures (Benjamin et al., 1994). However, in observational stud-
ies, we cannot rule out the existence of unmeasured confounding, which may distort
estimates of the fixed effects coefficients. In addition, the subject-specific model can
be computationally challenging for the study of rare diseases because a large number
of subjects is required.
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3.2.2.2 Population-Averaged Model
We assume the marginal expectation
h∗(νti ) = β
∗
0 + β
∗
1Z
t
i + β
∗
2t+ C(Z
t
i , G) (3.2)
where h∗ is the link function. C(Zti , G) is a function on exposure and group, which rep-
resents the heterogeneity across exposed and unexposed subgroups. The population-
averaged model is the marginal expectation of the subject-specific model. It does not
require knowledge of covariates or assumptions of the heterogeneity across individu-
als. Its coefficients are directly estimable from the aggregated data on exposure and
outcome, but do not have individual causal interpretation.
3.2.2.3 Connection between the Subject-Specific Model and the Population-
Averaged Model
In general, the two models can be related by integrating out X ti . In Zeger et al.
(1988),10 the cases of identity, log, probit, and logit link functions are discussed and
the corresponding mathematical relations between (β0, β1, β2) and (β
∗
0 , β
∗
1 , β
∗
2) are
listed in detail. The trend-in-trend method will be built on the population-averaged
model. With the purpose of making causal inferences on individuals with a binary
outcome, we require the link function h to be logistic such that deriving OR eβ1
is possible and the estimated quantity approximates the risk ratio obtained from a
cohort study of a rare outcome.
We next provide a mathematical derivation of the connection between the two
models and of how to estimate the causal OR using only data on trends in the
prevalence of both exposure and outcome in strata. We further show that under
plausible assumptions, the trend-in-trend method is unconfounded by measured and
unmeasured factors, provided that there are no trends in the prevalence of covariates
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that are correlated with the prevalence of the exposure over time. As the scenarios
that will lead to a confounded estimate in a trend-in-trend study are a subset of those
that will lead to a confounded estimate in a cohort study, the trend-in-trend design
is more resistant to potential confounding. However, unlike the cohort design, the
trend-in-trend design requires a strong time-trend in exposure, so is available in fewer
scenarios.
3.2.3 Estimation of the Odds Ratio
We first stratify the entire population into K strata according to the quintiles of
the estimated CPE. For each subgroup G and each time period t, we aggregate the
individual-level data to obtain quantities in the following table.
Outcome Y ti = 1 Outcome Y
t
i = 0 Total
Exposure Zti = 1 n
t
11 n
t
10 n
t
1
Exposure Zti = 0 n
t
01 n
t
00 n
t
0
Because h is the logit function, we have
E(Y ti |Zti , G) = E(E(Y ti |Zti , G,X ti ))
=
∫
exp(β0 + β1Z
t
i + β2t+ γ
TX ti )
1 + exp(β0 + β1Zti + β2t+ γ
TX ti )
dF (X ti |Zti , G) (3.3)
In general, there is no closed-form for the marginal mean as a function of the fixed
effects and β1 cannot be identified. However, an approximate form is available when
we impose the following assumptions:
(1) Covariates and time period have multiplicative effects on being exposed. i.e.,
P (Zti |X ti ) = h1(X t1)h2(t). h1 and h2 are two deterministic functions but un-
known.
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(2) Covariates for all individuals in any subgroup G are either time-invariant or
change randomly over time. They are random variables from an unknown dis-
tribution, i.e., P (X ti |G) = fG.
(3) The outcome is rare, and therefore we can omit the denominator of the integrand
in equation.
With these assumptions, we have:
E(Y ti |Zti , G) ≈
∫
exp(β0 + β1Z
T
i + β2t+ γ
TX ti )dF (X
t
i |Zti , G)
= exp(β0 + β1Z
T
i + β2t)E(γ
TX ti |Zti , G) (3.4)
In order to expand E(γTX ti |Zti , G), we compute the conditional distribution of co-
variates X ti given Z
T
i and G using the Bayes rule:
p(X ti |Zti = 1, G) =
p(Zti = 1, X
t
i |G)
p(Zti = 1|G)
=
p(Zti = 1|X ti , G)p(X ti |G)
p(Zti = 1|G)
=
p(Zti = 1|X ti )p(X ti |G)
p(Zti = 1|G)
=
h1(X
t
i )h2(t)fG
p(Zti = 1|G)
(3.5)
p(X ti |Zti = 0, G) =
p(Zti = 0, X
t
i |G)
p(Zti = 0|G)
=
p(Zti = 0|X ti , G)p(Xi|G)
p(Zti = 0|G)
=
p(Zti = 0|X ti )p(X ti |G)
p(Zti = 0|G)
=
fG − h1(X ti )h2(t)fG
p(Zti = 0|G)
(3.6)
Therefore,
p(X ti |Zti = 1, G) =
h1(X
t
i )h(t)fG
p(Zti = 1|G)
(3.7)
p(X ti |Zti = 0, G) =
fG − h1(X ti )h2(t)fG
p(Zti = 0|G)
(3.8)
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Define the following constants which only depend on G
C1G :=
∫
exp(γTX ti )h1(X
t
i )fGdX
t
i (3.9)
C2G :=
∫
exp(γTX ti )fGdX
t
i (3.10)
C3G :=
∫
h1(X
t
i )fGdX
t
i (3.11)
The marginal expectation E(Y ti |Zti , G) now becomes:
E(Y ti |Zti = 1, G) = exp(β0 + β1 + β2t)
C1G
C3G
(3.12)
E(Y ti |Zti = 0, G) = exp(β0 + β2t)
C2G − C1Gh2(t)
1− C3Gh2(t)
(3.13)
where C1G, C2G, C3G are unknown constants that depend on group.
Equations (3.12) and (3.13) are covariate-free. In other words, the marginal ex-
pectation of outcome is the same across treated/control individuals within the same
subgroup. Because each Y ti is binary, aggregating outcomes for the treated and un-
treated yields two binomial distributions. Consequently, we can write the parametric
likelihood for (nt11, n
t
10, n
t
01, n
t
00):
n11 ∼ Binomial(nt11 + nt10, eβ0+β1+β2t
C1G
C3G
) (3.14)
n01 ∼ Binomial(nt01 + nt00, eβ0+β2t
C2G − h2(t)C1G
1− h2(t)C3G
) (3.15)
(β0, β1, β2C1G, C2G, C3G) are unknown parameters and can be estimated by maximiz-
ing the above likelihood using an optimization algorithm. In particular, eβ1 is the
OR of interest. We have written a package for the R computing language called
TrendInTrend that performs this maximization and calculates the OR with its 95%
confidence interval given (nt11, n
t
10, n
t
01, n
t
00), t ∈ {1, 2, . . . , T} .
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3.3 Simulations: Comparing the Trend-in-trend De-
sign with the Cohort Study Method
Setup
We performed simulation studies to confirm that when unmeasured confounding is
present, the OR produced by the trend-in-trend method is negligibly biased (albeit
somewhat less precise) than that produced by a cohort study. We simulated a study
population of size 250,000 with 20 calendar quarters as study periods. The data were
generated according to the following procedure:
• Step 1: The covariates X ti are a five-dimensional vector with three entries gener-
ated from a multivariate Gaussian distribution and two other entries generated
from Bernoulli distributions with different success probabilities. Three scenar-
ios are examined: 1) covariates are sampled only once and fixed over time 2)
covariates are sampled independently for each calendar period 3) covariates are
sampled repeatedly for each calendar period with autocorrelation coefficient of
0.5.
• Step 2: Assign Zti to 1 with the probability of ea0+a1X
t
I+a2t+a3t
2
.
• Step 3: Simulate Y ti based on the subject-specific model and the choice of link
function h.
We choose (a0, a1, a2, a3) such that the simulated exposure prevalence has the up-
and-down shape shown in Fig. 5.1, which mimics the exposure trend of a drug
that becomes widely used after introduction, and is then withdrawn (e.g., rofecoxib).
However, the method should work for a unidirectional trend as well.
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Figure 3.1: Simulated overall exposure prevalence over time
Based on the CPEs estimated via logistic regression, the study population was
stratified into quintiles, i.e., K = 5. As expected, these strata, each with 50,000
individuals, had different trends in exposure prevalence. The CPE model included
all five covariates, as shown in Fig.5.2.
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Figure 3.2: Simulated exposure prevalence across subgroups based on CPE quintiles
over time.
We considered the following scenarios under the rare events assumption: (1), the
OR takes values of 1.0, 1.5, 2.0, and 2.5; (2) the strength of the CPE model has
three levels quantified by 0, 2, and 4 omitted confounders out of 5 confounders in
total, and a c-statistic is calculated for each level to gauge unobserved heterogeneity
in factors affecting outcome; (3) the number of CPE strata is either 5. We compare
the estimated OR with those calculated using the cohort method. The results, which
are the average values of 1000 simulations, are summarized in Tables 3.1, 3.2, and
3.3, corresponding three different scenarios of covariates sampling as described above.
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Results
True Number of C-statistic Trend-in-Trend Odds Ratio Cohort Study Odds Ratio
Odds Unmeasured of the CPE
Ratio Confounders Model Mean (% bias) SD Mean (% bias) SD
2.5 0 0.68 2.47 (-1.2) 0.0165 2.50 (0.0) 0.0092
2.5 2 0.63 2.45 (-2.0) 0.0170 4.75 (90.0) 0.0091
2.5 4 0.51 2.43 (-2.8) 0.0171 4.80 (92.0) 0.0091
2.0 0 0.68 1.97 (-1.5) 0.0147 2.01 (0.5) 0.0087
2.0 2 0.63 1.95 (-2.5) 0.0153 4.22 (111) 0.0081
2.0 4 0.51 1.94 (-3.0) 0.0131 4.25 (113) 0.0078
1.5 0 0.68 1.52 (1.3) 0.0101 1.50 (0.0) 0.0083
1.5 2 0.63 1.49 (-0.7) 0.0106 3.25 (117) 0.0081
1.5 4 0.51 1.48 (-1.3) 0.0108 3.30 (120) 0.0082
1.0 0 0.68 1.02 (2.0) 0.0082 0.99 (-1.0) 0.0079
1.0 2 0.63 1.02 (2.0) 0.0089 2.08 (108) 0.0074
1.0 4 0.51 1.02 (2.0) 0.0089 2.20 (120) 0.0073
Table 3.1: Comparison of the estimated causal odds ratio using the time-in-trend
design and the cohort study method. Confounders are sampled only once and fixed
over time.
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True Number of C-statistic Trend-in-Trend Odds Ratio Cohort Study Odds Ratio
Odds Unmeasured of the CPE
Ratio Confounders Model Mean (% bias) SD Mean (% bias) SD
2.5 0 0.62 2.46 (-1.6) 0.0198 2.50 (0.0) 0.0101
2.5 2 0.57 2.45 (-2.0) 0.0207 4.79 (91.6) 0.0104
2.5 4 0.41 2.41 (-3.6) 0.0212 4.91 (96.4) 0.0104
2.0 0 0.62 2.03 (-1.5) 0.0184 2.01 (0.5) 0.0091
2.0 2 0.57 1.94 (-3.0) 0.0191 4.28 (114) 0.0089
2.0 4 0.41 1.93 (-3.5) 0.0177 4.32 (116) 0.0090
1.5 0 0.62 1.53 (2.0) 0.0124 1.51 (0.7) 0.0092
1.5 2 0.57 1.53 (2.0) 0.0132 3.24 (116) 0.0088
1.5 4 0.41 1.46 (-2.7) 0.0129 3.38 (125) 0.0094
1.0 0 0.62 1.02 (2.0) 0.0098 0.99 (-1.0) 0.0087
1.0 2 0.63 1.03 (3.0) 0.0111 2.11 (111) 0.0083
1.0 4 0.51 0.97 (-3.0) 0.0112 2.27 (127) 0.0084
Table 3.2: Comparison of the estimated causal odds ratio using the time-in-trend
design and the cohort study method. The population is stratified into five subgroups
for the time-in-trend algorithm. Confounders are sampled independently for each
calendar period.
True Number of C-statistic Trend-in-Trend Odds Ratio Cohort Study Odds Ratio
Odds Unmeasured of the CPE
Ratio Confounders Model Mean (% bias) SD* Mean (% bias) SD*
2.5 0 0.66 2.46 (-1.6) 0.0195 2.50 (0.0) 0.0097
2.5 2 0.60 2.45 (-2.0) 0.0202 4.78 (89.2) 0.0098
2.5 4 0.41 2.42 (-3.2) 0.0207 4.87 (94.8) 0.0098
2.0 0 0.66 1.98 (-1.0) 0.0176 2.00 (0.0) 0.0087
2.0 2 0.60 1.94 (-3.0) 0.0185 4.23 (112) 0.0086
2.0 4 0.46 1.94 (-3.0) 0.0172 4.30 (115) 0.0085
1.5 0 0.66 1.53 (2.0) 0.0119 1.51 (0.7) 0.0087
1.5 2 0.60 1.52 (1.3) 0.0125 3.25 (117) 0.0086
1.5 4 0.46 1.47 (-2.0) 0.0122 3.35 (123) 0.0091
1.0 0 0.66 1.02 (2.0) 0.0094 0.99 (-1.0) 0.0081
1.0 2 0.60 1.02 (2.0) 0.0105 2.09 (109) 0.0079
1.0 4 0.46 1.03 (3.0) 0.0107 2.20 (120) 0.0080
Table 3.3: Comparison of the estimated causal odds ratio using the time-in-trend
design and the cohort study method. Confounders are sampled with autocorrelation
0.5 between any two consecutive calendar periods.
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As expected, when there were no unmeasured confounders, both the trend-in-trend
and cohort designs yielded ORs that were close to the truth. However, as the number
of unmeasured confounders increased, the ORs produced by the cohort design became
very biased, with biases ranging from 90% to 127%, while those from the trend-in-
trend design remained close to the truth, with bias ranging from -3.5% to 3%. The
standard deviations for the trend-in-trend method were one to two times as large as
those for the cohort method, which is to be expected as individual-level information
is partially lost when counts of outcomes are aggregated.
3.4 Application: Confirming THE Causal effect of
Rofecoxib on AMI
We applied the trend-in-trend method to ClinformaticsTM Data Mart Database (Op-
tumInsight, Eden Prairie, MN) to examine association between rofecoxib and AMI,
severe hypoglycemia, and non-vertebral bone fracture. We first identified all persons
age 18 years or older in Optum who received one or more prescriptions for rofe-
coxib during the study period from April 1, 2000 through Dec 30, 2004. For each
rofecoxib-exposed person episode, we ascertained the first month and the last month
of their continuous enrollment episode (or episodes, for persons with multiple en-
rollment episodes) during the study period. Thus, the unit of observation was the
enrollment episode, defined as a period of continuous enrollment for a person. A per-
son could contribute multiple episodes. For each rofecoxib-exposed episode, we ran-
domly sampled, without replacement, nine rofecoxib-unexposed enrollment episodes
with an enrollment start date on or before no more than one year of the rofecoxib-
exposed subjects enrollment start date, and with an enrollment end date on or after
the rofecoxib-exposed subjects enrollment end date. The rationale for this criterion
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was to ensure sufficient overlap in follow-up calendar time for exposed and unexposed
subjects. Thus, the analysis set contained ten times as many total episodes as there
were rofecoxib-exposed enrollment episodes. This was done to improve computational
efficiency versus including the entire study population.
We then fit a logistic regression to estimate the CPE using age, sex, diagnosis
of rheumatoid arthritis, and diagnosis of osteoarthritis as explanatory variables. For
rofecoxib-exposed subjects, these covariates were measured at their first prescription
date. For control subjects, these covariates were measured the same date as their
corresponding exposed subjects. The c-statistic was 0.608, which produced good sep-
aration of exposure prevalence across quintiles, as shown in Figure 3. The estimated
coefficients and standard deviations (as shown in parentheses) are 0.0228 (0.0001)
for continuous age, 0.1458 (0.0027) for female sex, 2.4418 (0.0124) for rheumatoid
arthritis, and -0.6444 (0.0191) for osteoarthritis.
The trend-in-trend method yielded an OR (95% confidence interval) for rofecoxib
and AMI of 1.23 (1.05, 1.44), which is consistent with the results of prior epidemiologic
studies: a 2005 meta-analysis yielded a pooled relative risk of 1.20 (1.10, 1.30) for
cohort and nested case-control studies (Hernández-Dı́az et al., 2006), and a more
recent meta-analysis reported a pooled relative risk of 1.34 (1.22, 1.48) (Varas-Lorenzo
et al., 2013). The ORs for the negative control outcomes, severe hypoglycemia and
non-vertebral bone fracture (neither of which is thought to be affected by rofecoxib),
were 1.09 (0.92, 1.28) and 0.84 (0.64, 1.09), which are both consistent with no effect
(Solomon et al., 2010).
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3.5 Discussion
We describe a novel hybrid ecologic-epidemiologic study design called the trend-in-
trend design, provide a mathematical derivation of the resulting odds ratio, use sim-
ulation to confirm that the results are less biased (albeit somewhat less precise) than
those of a cohort study when there is unmeasured confounding, and apply that method
to reproduce one positive and two null associations using real-world data. The results
of the empiric study using real-world data show that the design is readily applicable
and produces expected results.
Importantly, the trend-in-trend design avoids the Achilles heel of most epidemi-
ologic studies of healthcare interventions: conflation of receiving a treatment with
needing that treatment. Unlike cohort studies, the trend-in-trend design does not
assume no unmeasured confounders, but instead examines changes in outcome occur-
rence as a function of changes in exposure prevalence across strata with differential
time-trends in exposure. Therefore, the results of a trend-in-trend study will be un-
confounded unless there are unmeasured factors affecting outcome for which there
are time-trends in prevalence that are correlated with time-trends in exposure across
the strata defined by exposure trend. This could occur if there are co-interventions
for which the trend in use is positively correlated with trends in use of the exposure,
or alternatives for which the trend in use is negatively correlated with trends in use
of the exposure. As the scenarios that would produce a confounded trend-in-trend
estimate are a subset of those that would produce a confounded cohort estimate, the
trend-in-trend design is more resistant to confounding. However, the trend-in-trend
design is feasible only if there is a strong time-trend in exposure prevalence. Sim-
ilarly, the effect estimates produced using calendar period as an IV will be biased
if there is any time-trend in an unmeasured causal factor, whereas a trend-in-trend
study will be biased only if changes in the prevalence of such a factor are correlated
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with changes in exposure prevalence across CPE strata. The trend-in-trend design
therefore relaxes the assumptions under which use of calendar time as an IV is valid.
The causal contrast examined by the trend-in-trend approach deserves discussion.
It is the instantaneous effect of use of the exposure of interest rather than the ex-
posure(s) (if any) that the increasing (or declining) trend in use of the exposure of
interest displaced (or was displaced by). In the example of rofecoxib, this is likely
to be some combination of nonselective nonsteroidal anti-inflammatory drugs, opi-
oids, and no treatment. Thus, the trend-in-trend results may not mimic the results
of placebo-controlled trials evaluating the study treatment. Nevertheless, the causal
contrast with the alternatives that it displaces or is displaced by is arguably more
relevant from a public health perspective.
The main limitations of the trend-in-trend method are the need for a strong trend
in exposure prevalence and the reduced statistical precision that accompanies group-
level rather than individual-level analyses. Limitations of the current study include
the modest range of scenarios simulated and the fact that there is no empirical ex-
ample with a causal effect known with complete certainty.
Additional work is needed to improve the utility of the trend-in-trend design. Such
work should address control for measured factors for which there may be time-trends
that are correlated with time-trends in exposure across CPE strata, examination of
treatment effect heterogeneity, sequential analysis methods to allow multiple looks
while limiting type-1 error, and estimation of statistical power and detectable alter-
native.
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4
Squential Testing for the Trend-in-trend Design: an
Application to Drug Safety Surveillance In the
Presence of Unmeasured Confounding
Abstract
Post license drug safety surveillance is a critical step of the drug evaluation because
rare but serious adverse events may not be detected in pre-license randomized trials.
Sequential testing methods are powerful tools that facilitate early termination of the
drug usage when the drug exceeds the pre-assumed adverse event rate. However,
applying sequential tests on observational data can be misleading in the presence of
unmeasured confounders. We generalize the standard sequential testing to trend-in-
trend design settings that utilizes time trends in exposure prevalence and accounts
for both measured and unmeasured confounding. The performance of the proposed
approach is examined and compared to other approaches using simulation studies. We
also apply the method to Clinformatics Data Mart Database (OptumInsight, Eden
Prairie, MN) to test the risk of rofecoxib on acute acute myocardial infarction (AMI).
∗Joint work with Ashkan Ertefaie, Sean Hennessy, Charles Leonard, Dylan Small
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4.1 Introduction
Identifying all the adverse events (AE) of a drug may not be possible during the
pre-license randomized trials because such trials are often powered for efficiency (Du-
Mouchel, 1999; Davis et al., 2005). In fact, investigators often do not even have
a comprehensive list of all the possible AEs because treatments can interact with
patients’ genotype, characteristics and other treatments. Thus there are always pos-
sibilities of unexpected AEs. This motivates investigators to use big databases such
as electronic health records to study the risk of AEs among exposed and unexposed
groups. Another appealing feature of electronic health records is that because they
are updating frequently, investigators can monitor AEs in real time. For the public
health safety reasons, the drug use must be terminated as soon as there are enough
evidence of increased AEs rate which can only be done using sequential testing meth-
ods, see Ghosh et al. (2011); Mukhopadhyay and De Silva (2008); Govindarajulu
(2004).
Wald (Wald, 1945, 1947) proposed a sequential probability ratio test (SPRT),
where the null hypotheses of drug safety is rejected when the likelihood ratio exceeds
a predetermined critical value. SPRT approves the safety of the drug if by the end
of the study period, the likelihood ratio stays below the critical value. An important
feature of the test is that it adjusts for the p-values without knowing the number of
times that the test needs to be performed. One drawback of Wald test is that the
result highly depends on the specified alternative hypothesis. In fact, Kulldorf et.
al. Kulldorff et al. (2011) showed that for some alternative hypotheses, Wald test
can significantly delay or completely miss the signal. The latter paper proposed a
maximized sequential probability ration test (MaxSPRT) that handles the problem
by considering a composite alternative rather than simple (Hoel et al., 1976; Lachin,
1981; Meeker Jr, 1981; Van der Tweel et al., 1996). Sequential testing has also been
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extended to the Bayesian settings where a continuous-time Poisson process is assumed
for AEs (Lechner, 1962; Peskir and Shiryaev, 2000).
There are some sequential testing methods that are designed specifically for the
observation safety surveillance settings. Brown et. al. Brown et al. (2007) used a
Poisson based MaxSPRT that adjusts for confounding by stratifying patients based
on their baseline characteristics. However, this method requires reliable estimate of
the expected number of AEs under the null hypothesis which mat not be available
in many settings. Li (Li, 2009) addressed this shortcoming by proposing the condi-
tional sequential sampling procedure (CSSP) that preserves the type-I error rate by
implementing α-spending approaches. Li’s method also adjusts for confounding by
stratifying patients based on their baseline characteristics (see also Lan and DeMets
(1983) and Jennison and Turnbull (1997)). Group sequential generalized estimat-
ing equations (GS GEE) is another approach that adjusts for confounding using an
estimating equation based method (?). Lan and DeMets (Lan and DeMets, 1983)
also adopted the α-spending approach that adjusts for confounding in a regression
context (Jennison and Turnbull, 1997). For more detailed discussion on sequential
safety monitoring using observational data see Stratton (2012).
All the existing sequential testing methods in observational settings rely heavily
on an unstable assumption of no unmeasured confounding. Because electronic health
records are not, in general, collected for scientific purposes, the no unmeasured con-
founding assumption is unlikely to hold. We propose a sequential likelihood ratio
test with trend-in-trend design (SLR-TT) that is robust to unmeasured confounding
under certain assumptions. Per the discussion in Chapter 3, the trend-in-trend design
is a novel design that is used in observational settings to study causal effect of treat-
ments for which there are strong time trends. We show that the results obtained by
the existing methods may be misleading in the presence of unmeasured confounding
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while the proposed SLR-TT provides valid results.
4.2 Sequential Testing for the Trend-in-trend De-
sign
Inferences based on observational data are subject to bias due to unmeasured con-
founding. Ji et. al. Ji et al. (2016) proposed a new hybrid ecologic-epidemiologic
design called the trend-in-trend design, that utilizes time trends in exposure preva-
lence and accounts for both measured and unmeasured confounding. In the trend-
in-trend design we first estimate the cumulative probability of exposure (CPE; the
predicted probability of cumulative exposure based on variables other than exposure
and outcome) to stratify individuals and hence identify subgroups with different ex-
posure trends over the period of study. For example, when we define the treated
group as patients who have been exposed to treatment at least once during, then the
CPE is a logistic regression that includes patients characteristics and possibly time
as independent variable and the treatment indicator as dependent variable. In this
particular example, the statistical model of CPE is similar to the propensity score.
However, the CPE is only used to identify subgroups with different trends in expo-
sure prevalence and not for balancing purposes. At the second stage, we aggregate
the data for each subgroup and each time, and form a 2 × 2 table that shows the
number of patients who did and didn’t experience the AE and AEs among treated
and untreated group. Then a likelihood is derived and the parameters of interest are
estimated using MLE approach. In the sequel, we discuss the trend-in-trend design
and the proposed sequential testing approach in more details.
We study the effect of two treatment groups on the rate of adverse events using
a longitudinal data collected over a fixed period of time. Our dataset is composed of n
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i.i.d. trajectories of length T . The ith trajectory is the sequence (Xi, Di1, Yi1, ..., DiT , YiT )
where Xi is a vector of measured baseline characteristics that follows a distribution
F . Dit is the treatment status at time t and Yit is the indicator of whether an AE has
happened between time t−1 and t. Let g = 1, 2, ..., G denote the index for subgroups
after stratification based on CEP. The aggregated individual-level data based on each
subgroup g and time t consists of nt11g patients who were treated and experienced AEs
and nt01g patients who were untreated and experienced AEs. We also have the number
of patients who were treated (untreated) and did not experience an AE denoted as
nt10g (n
t
00g).
4.2.1 Derivation of the Likelihood Ratio
Assuming a logit model for AEs, the conditional mean of Yit given Dit, and g is
E(Yit|Dit, g) = E[E(Yit|Dit, g,Xi)]
=
∫
exp(β0 + β1Dit + β2t+ γ
>Xi)
1 + exp(β0 + β1Dit + β2t+ γ>Xi)
dF (Xi|Dit, g)
which does not have closed-form. However, assuming that the outcome is a rare
event and the covariates and time have multiplicative effects on being treated, i.e.
P (Dit|Xi) = h1(Xi)h2(t), the conditional mean can be written as
E(Yit|Dit, g) ≈
∫
exp(β0 + β1Dit + β2t+ γ
>Xi)dF (Xi|Dit, g)
= exp(β0 + β1Dit + β2t)E(γ
>Xi|Dit, g).
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Thus, β1 is the parameter of interest and null hypothesis can be written as H0 : β1 = 0.
Consequently, the likelihood in the trend-in-trend analysis is given by
L(β0, β1, β2) =
∏
g
∏
t
(
exp(β0 + β1 + tβ2)
C1g
C3g
)nt11g (
1− exp(β0 + β1 + tβ2)
C1g
C3g
)nt10g
(
exp(β0 + tβ2)
C2g − h2(t)C1g
1− h2(t)C3g
)nt01g (
1− exp(β0 + tβ2)
C2g − h2(t)C1g
1− h2(t)C3g
)nt00g
where
C1g =
∫
exp(γ>Xi)h1(Xi)fgdXi
C2g =
∫
exp(γ>Xi)fgdXi
C3g =
∫
h1(Xi)fgdXi,
are unknown constants that depend on stratum g and fg = f(Xi|g) Ji et al. (2016).
Following Shih et. al. Shih et al. (2010), the stopping rule is
τ = inf
{
t ≥ 1 : log L(β̂0, β̂1, β̂2)
L(β̂H00 , 0, β̂
H0
2 )
> c
}
,
where (β̂0, β̂1, β̂2) are the maximum likelihood estimates of the parameter vector
(β0, β1, β2) and (β̂
H0
0 , 0, β̂
H0
2 ) are the maximum likelihood estimates of the correspond-
ing parameters under the null hypothesis H0 : β1 = 0. The critical value c is approx-
imated using a Monte Carlo method that is discussed latter. The log-likelihood ratio
is
LLR = log
L(β̂0, β̂1, β̂2)
L(β̂H00 , 0, β̂
H0
2 )
=
∑
g
∑
t
nt11g(β̂0 + β̂1 + tβ̂2) + n
t
11g log(κg) + n
t
10g log(1− exp(β̂0 + β̂1 + tβ̂2)κg)
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+ nt01g(β̂0 + tβ̂2) + n
t
01g log(κ
t
g) + n
t
00g log(1− exp(β̂0 + tβ̂2)κtg)
− nt11g(β̂
H0
0 + tβ̂
H0
2 )− nt11g log(κg)− nt10g log(1− exp(β̂
H0
0 + tβ̂
H0
2 )κg)
− nt01g(β̂
H0
0 + tβ̂
H0
2 )− nt01g log(κtg)− nt00g log(1− exp(β̂
H0
0 + tβ̂
H0
2 )κ
t
g)
=
∑
g
∑
t
nt11g(β̂0 − β̂
H0
0 + β̂1 + tβ̂2 − tβ̂H02 ) + nt01g(β̂0 − β̂
H0
0 + tβ̂2 − tβ̂H02 )
+ nt10g log
1− exp(β̂0 + β̂1 + tβ̂2)κg
1− exp(β̂H00 + tβ̂H02 )κg
+ nt00g log
1− exp(β̂0 + tβ̂2)κtg
1− exp(β̂H00 + tβ̂H02 )κtg
where κg =
C1g
C3g
and κtg =
C2g−h2(t)C1g
1−h2(t)C3g .
4.3 The Sequential Likelihood Ratio Algorithm
1. With collected data up to T ≤ Tmax, fit a CPE model to stratify the population
and tabulate AEs in treated and control groups.
2. Estimate the log odds ratio and all nuisance parameters using MLE.
(β̂0, β̂1, β̂2, Ĉ1g, Ĉ2g, Ĉ3g).
3. Estimate nuisance parameters under the null hypothesis H0 : β1 = 0.
(β̂H00 , 0, β̂
H0
2 , Ĉ1g, Ĉ2g, Ĉ3g).
4. Calculate log likelihood ratios, LLR = (LLR(1), LLR(2), . . . , LLR(T )).
5. Reject the null at time τ using the following Stopping Rule
τ = inf {t ≤ T : LLR(t) > cT}
6. If the τ > T , proceed to time T + 1 and repeat step 1.
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4.3.1 Critical Value Approximation
The log likelihood ratio of the trend-in-trend design does not have known asymptotic
distribution and we approximate the critical value c using a Monte Carlo simulation
method that is outlined below:
1. Consider a set of candidates for cT , say C.
2. Given the estimated parameters (β̂H00 , 0, β̂
H0
2 , Ĉ
H0
1g , Ĉ
H0
2g , Ĉ
H0
3g ) under the null hy-
pothesis, generate K simulated datasets and obtain K realizations of LLR, i.e.,
each realization is a vector LLRk = (LLR
sim
k (1), ...LLR
sim
k (T )).
5. For any c ∈ C, calculate the proportion of times that a signal is detected by T
using the stopping rule. Let p̂(LLR > c|H0) =
∑
k I(τK<=T )
K
.
τk = inf
{
t ≤ T : LLRsimk (t) > c
}
6. Pick the value of cT such that p̂(LLR > c|H0) ≈ α(T ) where α(T ) is the type-I
error rate spent up to T .
4.4 Simulations: Comparing SLR-TT with CSSP
Setup
We present a simulation study with population size N=50,000 and calendar pe-
riods T = 10. We stratify the population based on CEPs into five subgroups,
hence each subgroup has 10,000 individuals. The vector of baseline covariates X =
(X1, X2, X3, X4, X5), where X1 ∼ N(2, 1), X2 ∼ N(2, 1), X3 ∼ Bernoulli(0.8),
X4 ∼ Bernoulli(0.2), and X5 ∼ Bernoulli(0.1).
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We consider three sets of simulation settings in which there are no unmeasured
confounders, 2 out of 5 unmeasured confounders, and 4 out of 5 unmeasured con-
founders. Within each set, the rejection rate and the average signal time of SLT-TT
and CSSP are evaluated under various scenarios with different values of the odds
ratio OR (which is approximately the risk ratio for rare events), and the exponent of
the α-spending function, where α(k) = α(k/K)γ and α = 0.05, γ = .5, 1, 2. Different
α-spending functions allocate different Type-I error we want to spend at each interim
test, as shown in Figure 4.1
Figure 4.1: Allocation of Type-I error rates for α-spending functions α(k) = α(k/K)γ
with α = 0.05 and γ = .5, 1, 2
At each calendar period t ≤ T , the treatment and outcome variables are generated
from
Zt ∼ Bernoulli(exp{α0 + α1X + α2t− α3t2})
Y t ∼ Bernoulli(exp{β0 + β1Zt + β2t+ β3X})
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where α0 = −15, α1 = (2, 1, 0.1, 0.1, 0.1), α3 = 0.031 and β0 = −4, β1 = log(OR), β2 =
0.001, β3 = 0.1(2, 1, 0.1, 0.1, 0.1). The parameter α2 represents the incidence rate of
exposure, which plays a critical role in the trend-in-trend analysis. Specifically, as the
value of α2 increases the power of the trend-in-trend analysis increases. To examine
the effect of the incidence rate of exposure in our sequential setting, we consider a
high incidence rate of exposure (α2 = 0.9 ) and a low incidence rate of exposure (α2 =
0.6). Moreover, we vary the odds ratio (OR) by setting β1 = log(2.5), log(2), log(1.5),
and 0. We parametrized the treatment assignment model so that the exposure has
an upward trend, which mimics the exposure trend of a newly approved drug that
becomes widely used after market debut (e.g., rofecoxib). The results are based on
1,000 datasets simulated from the generative models.
Results
Table 4.1 shows that when there is no unmeasured confounding, both SLR-TT and
CSSP achieve the 0.05 nominal error rate and when there is a relatively strong ex-
posure trend, i.e., α2 = 0.9, the proposed SLR-TT have more power than the CSSP.
The signal detection period is also shorter in SLR-TT. When the exposure trend is
weaker, i.e., α2 = 0.6, the SLR-TT has slightly less power than the CSSP and the
signal detection times are slightly longer as well.
Table 4.2 shows that, in the presence of unmeasured confounding, the CSSP
method results in an inflated type-I error rate that is roughly 3 time higher than
the nominal 0.05 rate, while the SLR-TT maintain the 0.05 rate.
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True Rejection Rate Rejection Periods
Odds SLR-TT CSSP SLR-TT CSSP
Ratio r=.5 r=1 r=2 r=.5 r=1 r=2 r=.5 r=1 r=2 r=.5 r=1 r=2
strong trend of exposure prevalence
1 .047 .046 .046 .047 .047 .047 4.144 4.921 6.890 4.681 5.462 7.002
1.5 .485 .481 .476 .337 .328 .327 3.591 4.845 5.689 4.026 5.373 6.155
2 .734 .717 .709 .581 .536 .522 2.680 3.750 4.717 3.441 4.335 5.702
2.5 1 1 1 .838 .815 .809 2.122 2.910 3.559 2.524 3.248 4.113
week trend of exposure prevalence
1 048 .046 .046 .048 .048 .047 4.566 6.226 7.021 4.130 5.966 6.771
1.5 .309 .293 .274 .372 .313 .290 4.788 5.871 6.513 4.210 5.502 6.193
2 .437 .426 .420 .538 .502 .485 4.012 4.755 5.787 3.745 4.586 5.228
2.5 .687 .671 661 .803 .770 .748 3.270 3.942 4.596 2.689 3.551 4.207
Table 4.1: Comparing rejection rates and average signal detection periods for different
odds ratio when there is no unmeasured confounding
Number of True Rejection Rate Rejection Periods
Unmeasured Odds SLR-TT CSSP SLR-TT CSSP
Confounders Ratio r=.5 r=1 r=2 r=.5 r=1 r=2 r=.5 r=1 r=2 r=.5 r=1 r=2
Strong Trend of Exposure Prevalence
1 .052 .049 .049 .127 .116 .113 4.529 5.210 6.223 4.487 5.209 6.138
2 1.5 .481 .476 .460 .493 .481 .478 4.211 5.010 5.980 4.209 5.053 5.991
2 .728 .711 .685 .657 .612 .601 2.993 3.985 5.102 3.401 4.355 5.366
2.5 1 1 .991 .837 .802 .793 2.367 3.206 3.981 2.647 3.690 4.351
1 .049 .047 .046 .189 .168 .150 4.561 5.412 6.311 4.424 5.210 6.126
4 1.5 .481 .477 .462 .505 .499 .484 4.422 5.340 6.080 4.168 4.943 5.941
2 .724 .709 .701 .733 .725 .699 3.302 3.994 5.137 3.329 3.954 5.114
2.5 1 1 .980 .844 .820 .809 2.514 3.366 4.205 2.988 3.769 4.310
Week Trend of Exposure Prevalence
1 .049 .049 .048 .114 .092 .089 5.257 6.402 7.124 5.016 6.101 7.087
2 1.5 .298 .290 .277 .390 .377 .363 4.810 5.991 6.796 4.625 5.730 6.419
2 .431 .419 .410 .591 .579 .554 4.106 4.857 5.987 3.891 4.657 5.578
2.5 .788 .779 .765 .804 .791 .782 3.354 4.056 4.818 3.102 3.924 4.927
1 .048 .047 .047 .141 .123 .116 5.710 6.617 7.218 5.317 6.352 7.204
4 1.5 .298 .287 .282 .397 .388 .370 5.340 6.125 6.981 4.890 5.896 6.715
2 .432 .414 .407 .607 .591 .573 4.284 4.946 6.082 4.033 4.882 5.919
2.5 .772 .766 .752 .820 .803 .794 3.509 4.277 5.161 3.216 4.049 5.002
Table 4.2: Rejection rates and average signal detection periods in the presence of
unmeasured confounding for different odds ratios
4.5 Application: Detecting the risk of Rofecoxib
using Sequential Data
We applied the SLR-TT method to Clinformatics Data Mart Database (OptumIn-
sight, Eden Prairie, MN) to test the risk of rofecoxib on acute acute myocardial infarc-
tion(AMI). The data were sampled as follows. We first identified all persons age 18
years or older in Optum who received one or more prescriptions for rofecoxib during
the study period from April 1, 2000 through Dec 30, 2004. For each rofecoxib-exposed
person episode, we ascertained the first month and the last month of their continuous
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enrollment episode (or episodes, for persons with multiple enrollment episodes) during
the study period. Thus, the unit of observation was the enrollment episode, defined
as a period of continuous enrollment for a person. A person could contribute mul-
tiple episodes. For each rofecoxib-exposed episode, we randomly sampled, without
replacement, nine rofecoxib-unexposed enrollment episodes with an enrollment start
date on or before no more than one year of the rofecoxib-exposed subjects enrollment
start date, and with an enrollment end date on or after the rofecoxib-exposed subjects
enrollment end date. The rationale for this criterion was to ensure sufficient overlap
in follow-up calendar time for exposed and unexposed subjects. Thus, the analysis
set contained ten times as many total episodes as there were rofecoxib-exposed enroll-
ment episodes. This was done to improve computational efficiency versus including
the entire study population.
We fit a logistic regression to estimate the CPE using age, sex, diagnosis of rheuma-
toid arthritis, and diagnosis of osteoarthritis as explanatory variables. For rofecoxib-
exposed subjects, these covariates were measured at their first prescription date. For
control subjects, these covariates were measured the same date as their correspond-
ing exposed subjects. The c-statistic was 0.608 and the estimated coefficients and
standard deviations (as shown in parentheses) are 0.0228 (0.0001) for continuous age,
0.1458 (0.0027) for female sex, 2.4418 (0.0124) for rheumatoid arthritis, and -0.6444
(0.0191) for osteoarthritis. We then stratified the study population into five strata
based on the estimated CPE quintiles.
Table 4.3 indicates that the proposed SLR-TT rejects the null hypothesis that
Rofecoxib has a potitive risk on AMI using sequentially available data at the third
calendar periods. The results are consistent for all three α-spending functions we are
considering, even though the critical values obtained via the Monte Carlo approxi-
mation are slightly different.
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However, the comparison method CSSP fails to detect the signal as the lowest
conditional probability that occurs at the forth calendar period is 0.1867, larger than
the overall Type-I error rate of 0.05.
Calendar Quarter 1 2 3 4 5 . . .
TT Likelihood Ratio 0.6534 1.5946 2.2753 2.9431 2.2654 . . .
Critical Value for r= .5 1.2718 1.6517 1.8669 1.9829 2.0164 . . .
Critical Value for r =1 1.4763 2.0165 1.9829 2.0531 2.1782 . . .
Critical Value for r= 2 1.9523 2.1126 2.1126 2.2651 2.4497 . . .
Reject the Null No No Yes Yes Yes . . .
Table 4.3: SLR-TT rejects the null hypothesis of no adverse events of AMI at the
third calendar period for all three α-spending functions
Figure 4.2: CSSP fails to reject the null hypothesis of no adverse events of AMI for
all three α-spending functions as the lowest conditional probability is 0.1867 at the
forth time interval
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5
What Do IV Estimates Mean when A Long Gap
Exists between IV Creation and Treatment:
Implication from Mendelian Randomization
5.1 Introduction
Mendelian randomization is a method of using genetic variants as instruments to
examine the causal effect of a modifiable environmental exposure on the risk of dis-
ease in epidemiological studies. Since Mendelian genes are inherited randomly and
independently at conception, they are independent of confounding factors that are
hard to be accurately accessed. Genetic variants usually remain constant throughout
an individual’s lifetime, thus are not affected by occurrences of diseases and changes
in exposure levels. As a results, reserve causation, which generally distorts causal
estimates, can be avoided using the Mendelian randomization Smith and Ebrahim
(2003). Validity of the method relies on one crucial yet untestable assumption, that
is there is no direct effect of Mendelian genes on disease nor any other mediated effect
∗Joint work with Dylan Small
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other than through the exposure of interest. This assumption, known as the exclu-
sion restriction assumption, needs to be justified using background knowledge of the
underlying biology and may incur a sensitivity analysis if necessary.
Benefiting from the development of a sophisticated range of instrumental variables
methods in econometrics, the Mendelian randomization has been widely applied to
cross-sectional and pooled panel data to estimate causal effects. One of the most
well-known estimation techniques is the generalized method of moments (GMM),
introduced by Hansen (1982), and the two-stage least squares (2SLS) regression is
often adopted as a special case of GMM when both responses and exposures are
continuous.
Causal conclusions drawn from the Mendelian randomization have interpretations
as changes in a response resulted from hypothetical interventions imposed on an expo-
sure. For instance, in a study that confirmed significant causal relationships between
body mass index (BMI) and blood pressure, FTO and MC4R genotypes were used as
instruments using data were collected from 37,027 unrelated individuals in Denmark
Timpson et al. (2009). The study concluded that, if a person were able to reduce
BMI by 10%, she would decrease systolic blood pressure by 3.85 mm Hg (95% CI:1.88
to 5.83 mm Hg, P=0.0002) and diastolic blood pressure by 1.79 mmHg (95% CI: 0.68
to 2.90 mmHg, P=0.002). Such interpretations correspond to difference between
counterfacturals in the potential outcome framework developed by Rubin (1974b),
which makes sense for static and discrete data. However, if we take a hard look at
the underlying data generative process instead of the format of the observed data,
we see that both BMI and blood pressure are more naturally to be considered as
time-continuous variables. In the broader context of many epidemiological studies,
biological variables of interest are often inherently dynamic yet observed discretely
by design of experiments or data collection procedures. That being said, most cross-
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sectional and pooled panel data that the Mendelian randomization is applied to are
actually discrete snapshots of dynamic processes, in which (1) the outcome, the ex-
posure, and covariates exhibit non-negligible serial correlations; (2) the outcome is an
important determinant of future exposure levels either directly or indirectly through
other unmeasured factors; (3) treatment levels are modifiable but can only change
gradually in a continuous fashion.
When observations are inherently dynamic, conclusions from the Mendelian ran-
domization are hard to be interpreted. Even worse is that the conventional exclusion
restriction assumption is ungrounded in dynamic settings so that estimators derived
based on static analysis could be severely biased from what they were intended to esti-
mate. To illustrate this point, we consider a simple scenario in which there exist serial
correlations, feedbacks, and unmeasured confinding, and approximate the dynamics
using measurements taken at equally-spaced infinitesimal intervals as shown in Fig-
ure 5.1. We use Yt, Dt, Ct, t ∈ {1, 2, . . . , T} to denote repeatedly observed outcomes,
exposure levels, and confounders respectively. The exclusion restriction assumption
asserts that the effect of the instrument Z on the outcome only goes through the en-
dogenous exposure whereas Figure 5.1 depicts multiple pathways from the instrument
Z to the last observed outcome YT going through either YT−1, DT , or DT−1. When
data are inherently dynamic, the exclusion restriction assumption is sensible only
in the conditional sense, i.e., conditioned on previous exposure levels and outcome
history, the instrument Z affects the current outcome YT only through the current
exposure level DT . Such conditional assumption is not implementable on discrete
observations using adjustment techniques like stratification or matching as units in a
study are almost impossible to have exactly the same historical trajectories.
As a results, the Mendelian randomization may distort the true causal relation-
ships without a careful modeling of the entire dynamic system.
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Figure 5.1: Illustration of multiple pathways from the instrument to the outcome
In the literature, many papers have addressed limitations of the Mendelian ran-
domization, most of them are centered around genetic heterogeneity, the lack of suit-
able polymorphisms for studying modifiable exposures of interest, and confounding
of genotype such as intermediate phenotype-disease associations Smith and Ebrahim
(2003); Lawlor et al. (2008); Nitsch et al. (2006). But its applicability to dynamic or
even longitudinal data has not received a lot of attention, at least to our knowledge.
We think it’s important to delve into this problem as many biological variables are
indeed dynamic processes. We shall take a mechanistic view by modeling reactions
among variables using stochastic differential equations and give an explicit formula
of the 2SLS estimator derived from discrete observations of the system. We conclude
that the 2SLS estimator is a biased estimator of the immediate causal effect, which
corresponds to the usual constant treatment effect in static settings.
The paper is organized as follows. In Section 5.2, we review the main idea and
limitations of the existing methods to provide practical insights into the potential
fallacy of the Mendelian randomization applied to dynamic data. In section 5.3,
we take a mechanistic view starting from generalizing notation and assumptions to
dynamic data in the presence of a static instrument. In particular, we extend the
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exclusion restriction assumption and relate it to local independence, a concept long
existed in the literature of graphical models. We use a linear dynamic system, whose
time-local presentation is described by a system of stochastic differential equations, to
depict the causal mechanism in the Mendelian randomization. In Section 5.4, we de-
rive the distribution of discrete measurements and contrast it with the true dynamic
mechanism. In Section 5.5, we investigate whether the Mendelian randomization is
applicable to discrete observations generated by the dynamic system. We show that
discrete observations of a s time-continuous process generally obscure the underly-
ing local independence between the outcome and the instrument. Hence, applying
the Mendelian Randomization to discrete observational data without explicit time
justification, could give insensible conclusions. We provide main results and simu-
lated examples. We find that the 2SLS estimator can be used to test for whether
the immediate causation is significantly different from zero but does not gauge its
magnitude. Based on our derivation, the 2SLS estimator has a form that involves the
truth immediate causation as well as many other properties of the dynamic model.
In the end, we provide conclusion and discussion.
5.2 Review and Limitations of Static Models
The idea of using Mendelian genes as instrumental variables can be viewed as carry-
ing out a randomized encouragement experiment to estimate the causal effect of an
exposure as an alternative to measure all confounders Holland (1988). In the simplest
case, each unit i is associated with a quadruple (Yi, Di, Zi, Ui), where
• Yi is the observed response or outcome variable.
• Di is the observed exposure or treatment assignment.
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• Zi is the randomly assigned encouragement intervention that encourages unit i
to experience a higher exposure level or enroll in the treatment group.
• Ui is the joined effect of all excluded variables. Ui is independent of Zi since Zi
is randomized by the study design.
To quantify the causal effect of Di on Yi, Holland (1988) proposed the following
additive linear constant effects model and β represents the average causal effect of
interest.
Yi = α + βDi + ρZi + Ui (5.1)
If Ui is correlated with Di, i.e. there are unmeasured confounders that affect both
the response and the exposure, coefficients on Di and Zi from least squares regression
are generally biased estimates of β and ρ. In order to consistently estimate the
additive effect of Di, the direct effect of the encouragement intervention is assumed
to be zero,i.e., ρ = 0. Under the exclusion restriction, Zi is independent of Yi − βDi.
One can test H0 : β = β0 using a Wilcoxon rank sum test comparing Yi − β0Si
for Zi = 1 and Zi = 0 and estimate β using the generalized method of moments
(GMM) introduced by Hansen (1982). In particular, the two-stage least squares
(2SLS) regression is commonly adopted as a special form of GMM when distributions
of both Yi and Di are reasonably normal and homoscedastic.
However, in many epidemiological contexts, Yi and Di are usually time-continuous.
For example, both BMI and blood pressure associated with an individual are dynamic
processes. One can apply the model 5.1 to a single-time measure or pooled repeated
measurements of BMI and blood pressure by justifying that the additive effect β
is unchanged over the course of study period. However, we argue that coefficients
obtained from such static analysis is not interpretable and the model together with
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its assumption is unrealistic given the underlying dynamics.
First of all, it’s unlikely for a biological exposure like BMI to change by a certain
amount in an instant and, if causal, it takes time for changes in blood pressure to be
observed. This means that Yi has to be measured with some time lag ∆t after Di is
measured and the interpretation of the additive effect β corresponds to the change
of Yi that takes ∆t for one unit change in Di to take effect. The size of ∆t is an
important property of the additive effect but is not incorporated explicitly in the
model 5.1.
Second, time-continuous variables usually exhibit non-negligible serial correlations
and the response can be an important determinant of future exposure levels either
directly or indirectly through other excluded variables. In the BMI and blood pressure
example, both variables are naturally auto-correlated. The level of blood pressure
could either promote or suppress the weight trajectory of an individual. On the one
hand, people with severe hypertension tend to limit physical activity to avoid a short
time increase in blood pressure. On the other hand, people with moderate level of
hypertension are likely to eat a healthy diet, limit the amount of alcohol intake, and
exercise regularly in order to lower blood pressure, which either directly or indirectly
result in weight loss. The model 5.1 is limited to static settings and does not capture
possible complicated reactions between current and previous values, and between
current outcome and future exposure levels.
Third, the exclusion restriction assumption is ungrounded for time-continuous
variables. Since Zi is associated with the exposure, it is correlated with the entire
history of exposure levels before Di is measured. Zi could therefore affect Yi through
the entire history of exposure levels, which is on top of the additive effect of Di.
Therefore, we are motivated to take a mechanistic perspective by proposing time-
continuous models that incorporate serial correlations and possible feedbacks for
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Mendelian randomization analyses. We will show in the next section that param-
eters in our time-continuous models have straightforward causal interpretations and
the exclusion restriction assumption is modified to ”local” exclusion restriction as-
sumption that is sensible for variables that are inherently dynamic.
5.3 Time-continuous Models for Mendelian Ran-
domization Analyses
5.3.1 Additive Linear AR(1) Models
We first extend the model 5.1 to the following additive linear AR(1) model by adding
first-order lagged terms and specifying how the exposure is affected by the previous
response. Parameters and error terms are functions of ∆t representing additive effects
that take ∆t to take effect from the corresponding variables.
Yt+∆t,i = α1(∆t) + β11(∆t)Yt,i + β12(∆t)Dt,i + ρ(∆t)Zi + εi(∆t) (5.2)
Dt+∆t,i = α2(∆t) + β12(∆t)Yt,i + β22(∆t)Dt,i + γ(∆t)Zi + ηi(∆t) (5.3)
Certain functional restrictions are required to equalize both sides of the equations 5.2
and 5.3 when ∆t = 0, which are α1(0) = α2(0) = β12(0) = β22(0) = ρ(0) = γ(0) =
εi(0) = ηi(0) = 0 and β11(0) = β21(0) = 1. This additive linear AR(1) mode reduces
to the simple additive linear constant effects model 5.1 if β11 is constantly zero and
if ∆t is not explicitly expressed.
Assumptions are needed so that Zi is still a ”valid” instrument in the extended
AR(1) model. The exogenous condition of Zi requires that Zi is independent of εi(∆t)
and ηi(∆t) for any ∆t, which is reasonable if Zi is randomized prior to the start of the
dynamic processes. As the Mendelian gene is inherited independently and randomly
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at conception for each individual, this assumption holds in Mendelian randomization
analyses. The relevance condition is extended to the statement that γ(∆t) 6= 0 for
any ∆t so that Zi is associated with the exposure throughout the entire processes.
A naive translation of the exclusion restriction assumption in Holland’s model 5.1
is that ρ(∆t) = 0,∀∆t. However, such condition is strong and contradicts our previous
arguments that Zi could affect the outcome through the exposure history between t
and t+∆t for a sizable ∆t. As an alternative, we find that a weakened condition, which
we call ”local exclusion restriction”, is better suited to restrict the direct effect from
Zi on the outcome during ∆t and paves the way for eventual mechanistic modeling
when ∆t shrinks to zero.
5.3.2 Local Exclusion Restriction
The local exclusion restriction states that
ρ(∆t)
∆t
→ 0, as ∆t→ 0 (5.4)
In words, both the direct effect of the instrument on the outcome over the course
of ∆t and the rate of the change in its magnitute converge to zero. For example,
ρ(∆t) = (∆t)2 conforms to the local exclusion restriction but is non-zero for a sizable
∆t.
The local exclusion restriction is related to the concept of local independence
formulated by Aalen (1987) for dynamic modeling of causality. The main idea of
local independence is that the intensity of one type of event is independent of certain
past events once we know about specific other past events and observed covariates)
while the local exclusion restriction basically asserts that the dependence of Yt+∆t,i on
Zi given Dt,i converges to zero in a faster rate than the diminishment of time interval
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∆t. Local independence has been applied to graphical models Didelez (2007, 2008)
and time series models Eichler (2007); Eichler and Didelez (2010) and received much
attention in the literature. But local exclusion restriction has never been considered
in IV models yet is crucial for Mendelian randomization analyses to quantify the local
behavior of how the Mendelian gene affects the outcome through the exposure.
5.3.3 Dynamic Models as Limits of AR(1) Models
Given the local exclusion restriction assumption, we assume further that all param-
eters (not including the error terms) are differentiable at ∆t = 0 and decrease ∆t to
zero. Specifically, we subtract off Yt,i and Dt,i on both sides of equations 5.2 and 5.3
respectively and take the limit as ∆t goes to an infinitesimal time interval dt.
Yt+∆t,i − Yt,i = α1(∆t) + (β11(∆t)− 1)Yt,i + β12(∆t)Dt,i + ρ(∆t)Zi + εi(∆t) (5.5)
Dt+∆t,i −Dt,i = α2(∆t) + β12(∆t)Yt,i + (β22(∆t)− 1)Dt,i + γ(∆t)Zi + ηi(∆t) (5.6)
Given the boundary conditions that α1(0) = α2(0) = β12(0) = β22(0) = ρ(0) = γ(0)
and β11(0) = β21(0) = 1, limits of parameters in equations 5.5 and 5.6 are the
first order derivatives at ∆t = 0 multiplied by dt. We also impose distributional
assumptions on εi(dt), ηi(dt) so that they are normally distributed and correlated
with each other. In particular, we write the error terms as linear transformations of
changes in two independent Wiener processes W 1t and W
2
t . It follows that the limit
of the additive linear AR(1) model is a system of stochastic differential equations
(SDEs) with parameters corresponding to instantaneous additive effects.
dYt,i = a1dt+ b11Yt,idt+ b12Dt,idt+ s11dW
1
t + s12dW
2
t (5.7)
dDt,i = a2dt+ b21Yt,idt+ b22Dt,idt+ rZidt+ s21dW
1
t + s22dW
2
t (5.8)
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in which α′1(0) = a1, β
′
11(0) = b11, β
′
12(0) = b12, α
′
2(0) = a2, β
′
21(0) = b21, β
′
22(0) =
b22, γ
′(0) = r. It is noteworthy ρ′(0) = 0 by the local exclusion restriction so that the
instrument Zi does not affect dYt,i.
From now on we shall use equations 5.7 and 5.8 to model the data generative pro-
cess for time-continuous response and exposure in the presence of a static instrument
variable. By our arguments, the newly proposed model is more suitable to describe
the relationship between BMI and blood pressure and may overturn the causal conclu-
sions in Timpson et al. (2009) drawn from discrete observations. We shall elaborate
on this point in the next section.
Before moving on to inference using discrete observations, we want to clarify our
contributions of proposing the above dynamic model in the form of SDEs. The use of
SDEs for modeling biological variables has been long existed in the literature because
SDEs resemble many natural laws in biology and medicine. A few examples are the
relationship between the number of CD4 cells and virus concentrations in HIV infec-
tion Røysland et al. (2012) and biological pathways for cell signaling Perelson (2002);
Bardwell et al. (2007). The causal interpretation of SDEs has also been investigated
previously by Sokol and Hansen (2014) using post-intervention equations resulting
from a perturbation in the functional form. Sokol and Hansen (2014) showed that,
under regularity conditions, the solution to a post-intervention SDE is the limit of
a sequence of interventions in Euler structural equation models, which are discrete
approximations of the preintervention (observational) SDE. As a result, prescribing
a hypothetical perturbation of a dynamic system has a counterfactual interpretation
situation as in discrete settings. However, no researchers have ever related SDEs to
the original encouragement design that defines a valid instrumental variable. Our
derivation of equations 5.7 and 5.8, as limits of AR(1) models, which are extension of
Holland’s constant additive effect models, reveals a natural way to employ instrumen-
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tal variables methods on dynamic data and, at the same time, exposes the potential
fallacy of drawing causal conclusions from discrete observations.
5.4 Inference from Discrete Measurements
Parameter estimation for SDEs has been highly tackled in several areas of math-
ematics and statistics, often motivated by financial applications; for reviews, see
Sørensen (2004); Bishwal (2008). Estimation methods are centered around construct-
ing approximations of the continuous-time observation likelihood, which require high
frequency data with a small time step between two successive observations Pedersen
(1995). Unfortunately, data in epidemiological studies and medical fields are usually
collected sparsely, in the time unit of month, calendar quarter, or even year. As a
result, parameters in equations 5.7 and 5.8 are generally not identifiable from sparse
discrete observations. From now on, we assume that discrete observations are snap-
shots of dynamic processes generated by equations 5.7 and 5.8 and investigate the
possibility of drawing sensible causal conclusions without estimation of their param-
eters.
5.4.1 Distribution of Discrete Measurements
We first compute distributions of discrete observations by aggregating dYt,i and dDt,i
using stochastic calculus. To ease computation, we write Xt,i = (Yt,i, Dt,i, Zi)
T and
dXt,i = (dYt,i, dDt,i, 0)
T . The dynamics of Xt,i is
dXt = µdt+ AXtdt+ σdWt (5.9)
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where
µ =

a1
a2
0
 , A =

b11 b12 0
b21 b22 r
0 0 0
 , σ =

s11 s12
s21 s22
0 0
 , dWt =
dW 1t
dW 2t
 (5.10)
We call A the transition matrix as it describes how local characteristics of Xi,t depend
functionally on past values. It is noteworthy that the upper right corner of A is
zero, which restricts the immediate direct effect of Zi on Yi,t and represents the local
exclusion restriction assumption of the instrument. By Ito’s isometry, the distribution
of Xt+∆t given Xt can be explicitly computed as a sum of deterministic terms and an
integral of a deterministic function with respect to a Wiener process with normally
distributed increments.
Xt+∆t = (e
A∆t − I)A−1µ+ eA∆tXt + σ
∫ ∆t
0
eA(∆t−s)dWs (5.11)
The distribution of Xt+∆t given Xt is thus normal and E(Xt+∆t|X0) = (eA∆t −
I)A−1µ + eA∆tXt, where e
A∆t =
∑∞
k=0
Ak(∆t)k
k!
. Therefore, associations between the
change in Xt,i over an infinitesimal interval and the change over an sizable interval
∆t is as the relationship between the transition matrix A and its exponential form
matrix eA∆t. These two matrices, though functionally related, have drastically dif-
ferent entries and structures. It particular, the upper right corner of eA∆t is likely to
be non-zero, which means that the local exclusion restriction would be smeared out
due to courser observations of the system. Moreover, the error terms as a stochastic
integral demonstrates the very complex covariance matrix as a function of ∆t.
The equation 5.11 shows that discrete observations with time step ∆t follow the
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additive linear AR(1) model bellow.
Yt+∆t,i = α1(∆t) + β11(∆t)Yt,i + β12(∆t)Dt,i + ρ(∆t)Zi + εi(∆t) (5.12)
Dt+∆t,i = α2(∆t) + β12(∆t)Yt,i + β22(∆t)Dt,i + γ(∆t)Zi + ηi(∆t) (5.13)
All parameters in equations 5.2 and 5.3 are functions of ∆t, representing the additive
effects of the corresponding variables that take ∆t to take effect. The aggregated
error terms εi(∆t) and ηi(∆t) are still normally distributed but their variances are
proportional to ∆t. We pay special attention to parameters of Yt,i, Dt,i and Zi, which
are related to parameters of the dynamic model via the matrix exponential function
and reduces to them when ∆t approaches zero.
A =

b11 b12 0
b21 b22 r
0 0 0
 , eA∆t =

β11(∆t) β12(∆t) ρ(∆t)
β21(∆t) β22(∆t) γ(∆t)
0 0 1
 (5.14)
Hence, one may get a different impression of the relationship between the response
and the exposure depending on whether one knows the true dynamic structure, rep-
resented by A, or one just has the empirical results for a few measurements of the
process. We shall use simulations to illustrate this point in the next section.
5.4.2 Change of Observational Associations Over Time
The first observation is that ρ(∆t) 6= 0, for ∆t > 0 and converges to zero in a faster
rate than the diminish of ∆t to conform to the local exclusion restriction of Zi. Such
result indicates that the instrument would have a direct effect on the outcome due
to courser observations of the dynamic process. The direct effect has nothing to do
with the physical law of instrument, but is introduced artificially because of latent
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interactions between the response and the exposure during the time interval ∆t.
The second observation is that all parameters in eA∆t depend on the size of
∆t, meaning that one may get a different impression of the relationship among
(Yt,i, Dt,i, Zi) . We use two numerical examples to investigate patterns of possible
changes of ρ(∆t) and β12(∆t), which is usually interpreted as the causal effect of the
exposure.
We consider two different transition matrices A1 and A2. Since all nonzero entries
of A1 are positive, both ρ(∆t) and β12(∆t) grow exponentially at ∆t increases, as
shown in the left panel of the Figure 5.2. A2 corresponds to a scenario in which the
exposure has a positive effect on the response but the increased response reversely
reduces the response in a larger magnitude. So the observational additive effect of
the exposure on the response β12(∆t) increases first and then drops to negative values
as ∆t becomes large, as shown in the right panel of the Figure 5.2
A1 =

.2 .2 0
.2 .2 .2
0 0 0
 A2 =

.1 .5 0
−1 .1 1
0 0 0
 (5.15)
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Figure 5.2: Illustration of variations in additive effect of the exposure and direct
effect of the instrument over time when the underlying mechanism follows a system
of stochastic differential equations. The left plot corresponds to A1 and the right plot
corresponds to A2
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5.4.3 Inference from Equally-spaced Repeated Measurements
Until now, we have made the point of the modeling the cause-effect relationship
as a time-local character for time-continuous variables and have discussed how the
mechanistic structure given by stochastic differential equations is often distorted when
we only get to observe the process at a few time points. We have also mentioned that
recovering the dynamic model which characterizes the true continuous cause-effect
relationship over time requires quite frequently measured data of a large number of
individuals. The questions is how ”frequent” is sufficient for different settings.
If the data are discrete measurements at regular times, say anthropometric mea-
surements every 6 months in a clinical trial for hypertension taking place over many
years. One could estimate eA∆t based on the additive linear AR(1) model 5.2 by
regressing Yt+∆t,i and Dt+∆t,i onto Yt,i, Dt,i and Zi. Theoretically, the obtained esti-
mates are asymptotically unbiased as the error terms are normally distributed with
mean zero and independent of all explanatory variables. But variances error terms
increase as ∆t becomes large, implying that a large sample size is needed to obtain
narrow confidence intervals of the estimates.
Suppose accurate estimation of eA∆t is available given appropriate sampling inter-
val ∆t and large enough study population, recovering the transition matrix A is still
not guaranteed simply because of the mathematical fact that logarithm of a matrix
is not an inevitable function. We have shown in the section 3.3 that eA∆t and A are
likely to have entries with opposite signs, hence we may even draw wrong qualitative
conclusions of the relationship between the exposure and the outcome using discrete
observations.
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5.5 Applying Static Analysis to Single Time Mea-
surement
In this section, we shall discuss the most extreme case in which we were only to see the
process once and possible consequences of applying the usual static analysis without
appropriately adjusting for the inherent dynamics. Suppose variables for each unit
are measured at some (unknown) time T after the start of the process. We investigate
whether it is still possible to get useful information from (YT,i, DT,i, Zi) and what
misleading results we would have by improperly applying static models. We shall use
2SLS regression as a demonstrating method.
Following the results in Section 5.4.1, we have
YT,i = α1(T ) + β11(T )Y0,i + β12(T )D0,i + ρ(T )Zi + εi(T ) (5.16)
DT,i = α2(T ) + β12(T )Y0,i + β22(T )D0,i + γ(T )Zi + ηi(T ) (5.17)
where Cov(εi(T ), ηi(T )) 6= 0 and (Y0,i, D0,i) are unknown initial states. Because Zi is
randomized prior to the start of the dynamic process, Cov(εi(T ), Z) = Cov(ηi(T ), Z) =
0.
5.5.1 Detecting Immediate Causation
Equations 5.16 and 5.17 reveal the true relationship between the measured response
YT,i and DT,i. If one falsely assume that there is no direct effect of Zi on YT,i, the
estimator obtained using the 2SLS regression is Ĉov(YT ,Z)
Ĉov(DT ,Z)
, which converges to the
following quantity
2̂SLS =
Ĉov(YT,i, Z)
Ĉov(DT,i, Z)
→ β12(T )Cov(D0,i, Zi) + ρ(T )V ar(Zi)
β22(T )Cov(D0,i, Zi) + γ(T )V ar(Zi)
(5.18)
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If we further assume that the instrument Zi is independent of the initial state of
exposure D0,i,the 2SLS estimator estimates the ratio of the direct effect of the instru-
ment on YT,i to the direct effect of the instrument on DT,i, which has no straightfor-
ward causal interpretation.
2̂SLS =
Ĉov(YT,i, Z)
Ĉov(DT,i, Z)
→ ρ(T )V ar(Zi)
γ(T )V ar(Zi)
(5.19)
However, the 2SLS estimator can be used to detect the immediate causation and we
have the following theorem.
Theorem 1. If the exposure has no immediate causation on the response and
the instrument satisfies the local exclusion restriction, i.e., dYi,t does not depend on
Di,t and Zi, then neither the exposure nor the instrument has a direct effect on the
response at any time.
Intuitively, all pathways from Zi to YT,i are blocked although YT,iand DT,i are still
correlated due to confounding and reverse causation. Theorem 1 also implies that if
dynamics between the exposure, the outcome, and the instrument follow equations 5.7
and 5.8 with constant parameters and the exposure has no immediate causation on
the response, i.e., b12 = 0, then the 2SLS estimator derived from observations at any
time is asymptotically zero.
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Figure 5.3: Illustration of the 2SLS estimator to detect immediate causal effect. The
left and right plots correspond to A1 and A2 respectively with b12 = 0.
5.5.2 Possible Misleading Results
Even though the 2SLS estimator can be used to detect the immediate causation, it
does not give a sensible estimate of its magnitude. If b12 6= 0, the 2SLS estimator is
generally a biased estimator of the immediate causal effect b12 and we use simulations
to investigate the bias of 2̂SLS. We consider two different setups with the following
parameters and the corresponding results are summarized in the table 5.1
A1 =

.2 b12 0
.2 .2 .2
0 0 0
 A2 =

.1 b12 0
−1 .1 .1
0 0 0
 (5.20)
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A b12 T=1 T=5
ρ(T ) γ(T ) 2̂SLS (SD) ρ(T ) γ(T ) 2̂SLS (SD)
.5 0.058 0.225 0.254 (0.066) 3.141 2.745 1.129 (0.062)
.75 0.087 0.227 0.375 (0.073) 5.257 3.364 1.550 (0.075)
A1 1 0.116 0.229 0.510 (0.081) 7.800 4.062 1.905 (0.089)
1.25 0.146 0.231 0.638 (0.086) 10.822 4.847 2.214 (0.104)
1.5 0.176 0.233 0.756 (0.095) 14.382 5.726 2.497(0.115)
.5 0.256 0.964 0.257 (0.013) 2.385 -1.372 -1.764 (0.019)
.75 0.376 0.921 0.416 (0.014) 1.419 -1.956 -0.676 (0.016)
A2 1 0.491 0.881 0.546 (0.016) 0.371 -1.618 -0.187(0.019)
1.25 0.601 0.841 0.705 (0.017) -0.360 -0.913 0.499 (0.032)
1.5 0.705 0.802 0.882 (0.020) -0.645 -0.171 3.709 (0.141)
Table 5.1: 2SLS estimator as a biased estimator of the immediate causal effect with
possibly negative signs
5.6 Summary and Discussions
In fields such as medicine, biology, and social science, variables of interest can be
time-continuous. Given the same exposure trajectory and starting values, the sam-
ple path of the exposure varies between persons and time points. Assuming that
the underlying dynamics following s diffusion process, we proved that local exclusion
restriction would be smeared out and additional connections with no causal interpre-
tations would be introduced due to courser observations of the system. In particular,
the Mendelian randomization with the 2SLS regression cannot be applied to discrete
measures to gauge the magnitude of causation. Significance level of the Mendelian
randomization, however, can be used to detect the existence of causal relationship
between the exposure and the outcome. These complete paths would of course never
be available to the researcher who would merely observe the process at a few dis-
tinct locations. It is expected that one would benefit from finer observations, but
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the time between consecutive measures relative to the length of study needs further
investigation. Now we revisit the BMI and blood pressure example that concluded
10% increase in body mass index would increase systolic blood pressure and diastolic
blood pressure by 3.85 mm Hg and1.79 mmHg, respectively. Based on Theorem 1,
the study confirms that BMI affects blood pressure in a cause-effect fashion, but the
numerical conclusions on cumulative changes in blood pressure caused by a given
percentage change in BMI are not sensible.
Of course the actual mechanism for a biological process can be far more complex
than our working model. For instance, parameters can change over time when the
system is non-stationary. We opt for the simplest model to demonstrate that asso-
ciations in discrete observations may be dramatically different from dependencies in
the underlying system, therefore inferring causality from discrete observations could
be problematic.
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